US9334500B2 - Methods and pharmaceutical compositions for treating cancer - Google Patents

Methods and pharmaceutical compositions for treating cancer Download PDF

Info

Publication number
US9334500B2
US9334500B2 US14/348,365 US201214348365A US9334500B2 US 9334500 B2 US9334500 B2 US 9334500B2 US 201214348365 A US201214348365 A US 201214348365A US 9334500 B2 US9334500 B2 US 9334500B2
Authority
US
United States
Prior art keywords
ubash3b
cancer
seq
expression
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US14/348,365
Other languages
English (en)
Other versions
US20140335106A1 (en
Inventor
Qiang Yu
Shuet Theng Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Assigned to AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH reassignment AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEE, Shuet Theng, YU, QIANG
Publication of US20140335106A1 publication Critical patent/US20140335106A1/en
Application granted granted Critical
Publication of US9334500B2 publication Critical patent/US9334500B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Definitions

  • the present invention generally relates to methods and pharmaceutical compositions for treating cancer.
  • the present invention also relates to methods for determining suitability of a cancer patient for treatment using the disclosed methods and pharmaceutical compositions, and determining disease outcome.
  • Cancer is a leading cause of disease worldwide and according to a global study on cancer in 2008, an estimated 12.7 million new cancer cases occurred worldwide in that year alone. Of the various types of cancers, breast, lung, bowel and prostate cancers together account for over half of all new cancers worldwide. Accordingly, it is particularly important to develop new and more effective therapies against these particular types of cancer.
  • TNBC Triple-Negative Breast Cancer
  • ER estrogen receptor
  • PR progesterone receptor
  • Her2 human epidermal growth factor 2
  • TNBC Triple-Negative Breast Cancer
  • EGFR targeted therapy represents one such example.
  • the rationale for targeting EGFR is based on the observation that TNBC often harbors, EGFR overexpression, leading to hyperactivation of multiple downstream oncogenic kinase signaling pathways such as AKT and ERK.
  • EGFR inhibitors have thus far shown limited favorable response during clinical trials.
  • PARP poly-ADP ribose) polymerase
  • breast tumors in particular TNBCs
  • TNBCs are highly heterogeneous and utilize multiple mechanisms to enable the aggressive phenotypes, such as invasion and metastasis. These pathways may then get integrated as specific signaling steps that collectively contribute to the disease progression.
  • Pathways and mechanisms involved in invasion and metastasis often involve transcriptional reprogramming induced by deregulated transcriptional regulators, such as NF- ⁇ B, ETS1, Notch, TGF- ⁇ , and Polycomb protein EZH2, as well as microRNAs such as miR-200s.
  • Downstream targets of these regulators may participate in various rate-limiting steps in disease progression, including epithelial to mesenchymal transition (EMT) (ZEB1/2, TWIST and CDH1), cancer stem cell self-renewal (IL-6 and STAT3), and distant metastasis (Sec23a and VCAM1).
  • EMT epithelial to mesenchymal transition
  • IL-6 and STAT3 cancer stem cell self-renewal
  • Sec23a and VCAM1 distant metastasis
  • a method of treating cancer by inhibiting expression of ubiquitin associated and SH3 domain containing B (UBASH3B) gene or by inhibiting the activity of UBASH3B protein or a functional variant thereof.
  • UBASH3B ubiquitin associated and SH3 domain containing B
  • a method of sensitizing and/or re-sensitizing a cancer patient to a treatment with one or more chemotherapeutic agents by inhibiting expression of UBASH3B gene or by inhibiting the activity of UBASH3B protein or a functional variant thereof.
  • an siRNA directed against the nucleic acid transcribed from the UBASH3B gene.
  • an siRNA directed against the nucleic acid transcribed from the ETS1 gene.
  • an shRNA directed against the nucleic acid transcribed from the UBASH3B gene.
  • a UBASH3B antagonist in the manufacture of a medicament for treating cancer, wherein said UBASH3B antagonist is capable of inhibiting expression of UBASH3B gene or inhibiting the activity of UBASH3B protein or a functional variant thereof.
  • a UBASH3B antagonist in the manufacture of a medicament for sensitizing and/or re-sensitizing a cancer patient to a treatment with one or more chemotherapeutic agents, wherein said UBASH3B antagonist is capable of inhibiting expression of UBASH3B gene or inhibiting the activity of UBASH3B protein or a functional variant thereof.
  • a method of determining cancer patient prognosis comprising the steps of:
  • a ninth aspect there is provided a method of determining a cancer patient's susceptibility to treatment with an EGFR antagonist, wherein the method comprises the steps of:
  • a method of determining a cancer patient's susceptibility to a chemotherapeutic agent comprising the steps of:
  • a pharmaceutical composition for preventing cancer invasion and/or metastasis comprising a UBASH3B antagonist, and an agent selected from the group consisting of a CBL agonist, and a EGFR antagonist.
  • the term “about”, in the context of concentrations of components of the formulations, typically means+/ ⁇ 5% of the stated value, more typically +/ ⁇ 4% of the stated value, more typically +/ ⁇ 3% of the stated value, more typically, +/ ⁇ 2% of the stated value, even more typically +/ ⁇ 1% of the stated value, and even more typically +/ ⁇ 0.5% of the stated value.
  • range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
  • UBASH3B also known as STS1 and used interchangeably herein
  • modulation of the UBASH3B gene expression and/or the activity of UBASH3B protein results in modulation of CBL ubiquitin ligase dephosphorylation and activity, and EGFR gene expression and/or the activity of EGFR protein.
  • UBASH3B acts as a downstream target of invasive regulators ETS1 and miR-200a, and exerts its oncogenic effect through its phosphatase activity by dephosphorylation and inactivation of CBL ubiquitin ligase.
  • UBASH3B By dephosphorylating and inactivating CBL ubiquitin ligase, UBASH3B has been found to upregulate gene expression and/or activity of EGFR protein, which is implicated in the malignant growth of a tumor, its invasion and/or metastasis. Thus, UBASH3B can be a therapeutic target in development of new therapies for cancer, particularly cancers which are associated with EGFR gene and/or protein expression such as TNBC, prostate cancer, lung cancer, brain cancer and colon cancer.
  • the present disclosure provides methods and pharmaceutical compositions for treating cancer using a compound capable of modulating expression of the UBASH3B gene, and/or the activity of the UBASH3B protein or a functional variant thereof.
  • the present disclosure also provides methods and pharmaceutical compositions for sensitizing and/or re-sensitizing a cancer patient to a treatment with one or more chemotherapeutic agents using a compound capable of modulating expression of the UBASH3B gene, and/or the activity of the UBASH3B protein or a functional variant thereof.
  • the expression of UBASH3B is positively correlated with the expression of ETS1 and EGFR, and negatively correlated with the expression of miR-200a and CBL.
  • the present disclosure further provides methods to facilitate selection of a suitable treatment for a cancer patient, optimization of treatment regimen, and prognosis of disease outcome based on the expression level of UBASH3B.
  • modulator compounds such as UBASH3B antagonists
  • a pathological condition such as cancer
  • ETS1 antagonists miR-200a agonists
  • CBL agonists CBL agonists
  • EGFR antagonists any one or more which may be used in combination therapy with UBASH3B antagonists to treat a pathological condition, such as cancer, in a patient.
  • modulate refers to regulating, effecting or influencing in any way the expression of a gene (for example, the UBASH3B gene) and/or the activity of a protein (for example, the UBASH3B protein or a functional variant thereof).
  • modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of the protein.
  • a modulator compound may be, for example, an agonist, antagonist or inhibitor of any one or more pathways or intermediate compounds in the pathways leading to the expression of the gene and/or activity of its protein.
  • Modulator compounds may include synthetic agents or natural compounds, including but not limited to peptide, nucleic acid and non-proteinaceous organic molecules.
  • the modulator compound is an UBASH3B antagonist.
  • a “UBASH3B antagonist” refers to a molecule (peptidyl or non-peptidyl) capable of neutralizing, blocking, inhibiting, abrogating or interfering with UBASH3B-associated activities including UBASH3B activation, its binding to one or more UBASH3B receptors, its tyrosine phosphatase activity, or its downstream molecular signaling (for example, CBL dephosphorylation), or decreasing, inhibiting or abrogating the gene expression or protein level of UBASH3B.
  • the UBASH3B antagonist may reduce or inhibit, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, the expression level or biological activity of UBASH3B.
  • the modulator compound is an inhibitor of the tyrosine phosphatase activity of the UBASH3B protein or a functional variant thereof.
  • the inhibitor of the tyrosine phosphatase activity is an agent capable of mutating the wild-type UBASH3B such that the tyrosine phosphatase activity is reduced or lost.
  • Such mutants may be prepared using methods known in the art, for example using site-directed mutagenesis.
  • UBASH3B antagonists useful in the disclosed methods include peptidyl or non-peptidyl compounds that specifically bind UBASH3B, such as oligonucleotides, antibodies, inorganic molecules, ribozymes that target UBASH3B, and UBASH3B aptamers.
  • oligonucleotides that can act as UBASH3B antagonists include, but are not limited to, interfering ribonucleic acid (such as siRNA, shRNA and miRNA), protein nucleic acids (PNAs), and locked nucleic acids (LNAs).
  • interfering ribonucleic acid such as siRNA, shRNA and miRNA
  • PNAs protein nucleic acids
  • LNAs locked nucleic acids
  • RNA refers to a ribonucleic acid (RNA) or RNA analog comprising between about 10 to 50 nucleotides (or nucleotide analogs) capable of directing or mediating the RNA interference pathway. These molecules can vary in length and can contain varying degrees of complementarity to their target messenger RNA (mRNA) in the antisense strand.
  • mRNA target messenger RNA
  • siRNA includes duplexes of two separate strands, i.e. double stranded RNA, as well as single strands that can form hairpin structures comprising a duplex region.
  • the siRNA may have a length of between about 10 to 50 nucleotides, or between about 15 to 50 nucleotides, or between about 20 to 50 nucleotides, or between about 25 to 50 nucleotides, or between about 30 to 50 nucleotides, or between about 35 to 50 nucleotides, or between about 40 to 50 nucleotides, or between about 10 to 45 nucleotides, or between about 10 to 40 nucleotides, or between about 10 to 35 nucleotides, or between about 10 to 30 nucleotides, or between about 10 to 25 nucleotides, or between about 10 to 20 nucleotides, or between about 15 to 50 nucleotides, or between about 15 to 35 nucleotides, or between about 15 to 30 nucleotides, or between about 15 to 25 nucleotides. In one embodiment, the siRNA has a length of between 15 to 30 nucleotides.
  • siRNA degradation may occur when the anti-sense strand, or guide strand, of the siRNA directs the RNA-induced silencing complex (RISC) to cleave its target mRNA bearing a complementary sequence.
  • RISC RNA-induced silencing complex
  • the siRNA may be complementary to any portion of varying lengths on the UBASH3B gene.
  • the siRNA may also be complementary to the sense strand and/or the anti-sense strand of the UBASH3B gene. Accordingly, in one embodiment, siRNA treatment may be used to silence the UBASH3Bgene, thereby depleting the UBASH3B protein downstream.
  • the siRNA may be directed against fragments of the nucleic acid transcribed from the gene. Accordingly, in one embodiment, the siRNA may comprise a sequence that is complementary to any fragment of the gene (such as the UBASH3B gene) or functional variants thereof. Such functional variants thereof may comprise at least one modified or substituted nucleotide. Functional modifications and/or substitutions of the siRNA may be performed by methods known in the art.
  • the siRNA used as UBASH3B antagonist comprises a sequence selected from the group consisting of: 5′-CCGGCUUAUUUGAGUGGAC-3′ (SEQ ID NO: 1), 5′-CCUCAUAAGAAGCAGCUAC-3′ (SEQ ID NO: 2), and 5′-GCACUGCAACUGAGAAAUU-3′ (SEQ ID NO: 3), or functional variants thereof.
  • the siRNA is 5′-CCGGCUUAUUUGAGUGGAC-3′ (SEQ ID NO: 1), or functional variants thereof.
  • the siRNA is 5′-CCUCAUAAGAAGCAGCUAC-3′ (SEQ ID NO: 2), or functional variants thereof.
  • the siRNA is 5′-GCACUGCAACUGAGAAAUU-3′ (SEQ ID NO: 3), or functional variants thereof.
  • RNA refers to a unimolecular RNA that is capable of performing RNA interference (RNAi) and that has a passenger strand, a loop and a guide strand.
  • the passenger and guide strand may be substantially complementary to each other.
  • shRNA may also include nucleic acids that contain moieties other than ribonucleotide moieties, including, but not limited to, modified nucleotides, modified internucleotide linkages, non-nucleotides, deoxynucleotides, and analogs of the nucleotides mentioned thereof.
  • the shRNA used as UBASH3B antagonist comprises a sequence selected from the group consisting of: 5′-GCTCAGAATCATTTAGCATAT-3′ (SEQ ID NO: 41), and 5′-GCGTTCAGACTGCACATAATA-3′ (SEQ ID NO: 42), or functional variants thereof.
  • the shRNA is 5′-GCTCAGAATCATTTAGCATAT-3′ (SEQ ID NO: 41), or functional variants thereof.
  • the shRNA is 5′-GCGTTCAGACTGCACATAATA-3′ (SEQ ID NO: 42), or functional variants thereof.
  • miRNAs down-regulate their target mRNAs.
  • the term “miRNA” generally refers to a single stranded molecule, but in some embodiments, may also encompass a region or an additional strand that is partially (between 10% and 50% complementary across the length of strand), substantially (greater than 50% but less than 100% complementary across the length of strand) or fully complementary to another region of the same single-stranded molecule or to another nucleic acid.
  • nucleic acids may encompass a molecule that comprises one or more complementary or self-complementary strand(s) or “complements” of a particular sequence comprising a molecule.
  • precursor miRNA may have a self-complementary region, which is up to 100% complementary.
  • miRNA probes or oligonucleotides of the invention can include, can be or can be at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to their target.
  • the UBASH3B antagonist is an antibody (for example, an anti-UBASH3B antibody) or an antigen-binding fragment thereof.
  • An “anti-UBASH3B antibody” is an antibody that binds to UBASH3B with sufficient affinity and specificity.
  • the antibody may bind UBASH3B with a K a value of between about 100 nM to 1 pM.
  • Antibody affinities may for example be determined using methods known in the art, for example by a surface plasmon resonance based assay (such as the BIAcore assay); an enzyme-linked immunoabsorbent assay (ELISA); and, competition assays (for example, radioimmunoassays).
  • An anti-UBASH3B antibody will usually not bind to other UBASH3B homologues, nor other members of of its family such as UBASH3A (also known as STS2), nor other tyrosine phosphatases.
  • antibody includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (for example, bispecific antibodies), monovalent antibodies, multivalent antibodies, and antibody fragments so long as they exhibit the desired biological activity.
  • Antibody fragments may comprise only a portion of an intact antibody, wherein the portion preferably retains at least one, preferably most or all, of the functions normally associated with that portion when present in an intact antibody.
  • an antibody fragment comprises an antigen binding site of the intact antibody and thus retains the ability to bind antigen.
  • an antibody fragment for example one that comprises the Fc region, retains at least one of the biological functions normally associated with the Fc region when present in an intact antibody, such as FcRn binding, antibody half life modulation, ADCC function and complement binding.
  • an antibody fragment is a monovalent antibody that has an in vivo half life substantially similar to an intact antibody.
  • such an antibody fragment may comprise an antigen binding arm linked to an Fc sequence capable of conferring in vivo stability to the fragment.
  • the antibody may also be a “blocking” antibody or an antibody “antagonist” which inhibits or reduces biological activity of the antigen it binds. In some embodiments, blocking antibodies or antagonist antibodies completely inhibit the biological activity of the antigen.
  • an “antibody variant” as used herein refers to an amino acid sequence variant of the species-dependent antibody wherein one or more of the amino acid residues of the species-dependent antibody have been modified. Such variants necessarily have less than 100% sequence identity or similarity with the species-dependent antibody.
  • the antibody variant will have an amino acid sequence having at least 75% amino acid sequence identity or similarity with the amino acid sequence of either the heavy or light chain variable domain of the species-dependent antibody, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%. Identity or similarity with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical (i.e. same residue) or similar (i.e.
  • the modulator compound is an ETS1 antagonist.
  • a “ETS1 antagonist” (such as an “ETS1 inhibitor”) refers to a molecule (peptidyl or non-peptidyl) capable of neutralizing, blocking, inhibiting, abrogating, reducing, or interfering with ETS1 expression and/or its activities including its binding to one or more ETS1 receptors, its transcription activity, or its upregulation of UBASH3B gene expression or protein activity.
  • the ETS1 antagonist may reduce or inhibit, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, the expression level or biological activity of ETS1.
  • ETS1 antagonists useful in the disclosed methods include peptidyl or non-peptidyl compounds that specifically bind ETS1, such as oligonucleotides, antibodies, and inorganic molecules.
  • exemplary oligonucleotides that can be used as ETS1 antagonists include, but are not limited to, interfering ribonucleic acid (such as siRNA, shRNA and miRNA), protein nucleic acids (PNAs), and locked nucleic acids (LNAs).
  • the siRNA that can be used as ETS1 antagonist may have a length of between about 10 to 50 nucleotides, or between about 15 to 50 nucleotides, or between about 20 to 50 nucleotides, or between about 25 to 50 nucleotides, or between about 30 to 50 nucleotides, or between about 35 to 50 nucleotides, or between about 40 to 50 nucleotides, or between about 10 to 45 nucleotides, or between about 10 to 40 nucleotides, or between about 10 to 35 nucleotides, or between about 10 to 30 nucleotides, or between about 10 to 25 nucleotides, or between about 10 to 20 nucleotides, or between about 15 to 50 nucleotides, or between about 15 to 35 nucleotides, or between about 15 to 30 nucleotides, or between about 15 to 25 nucleotides.
  • the siRNA has a length of between 15 to 30 nucleotides.
  • the siRNA used as ETS1 antagonist comprises a sequence selected from the group consisting of: 5′-CCCAGCCUAUCCAGAAUCC-3′ (SEQ ID NO: 4) and 5′-GGAAUUACUCACUGAUAAA-3′ (SEQ ID NO: 5), or functional variants thereof.
  • the siRNA used as ETS1 antagonist comprises 5′-CCCAGCCUAUCCAGAAUCC-3′ (SEQ ID NO: 4), or functional variants thereof.
  • the siRNA used as ETS1 antagonist comprises 5′-GGAAUUACUCACUGAUAAA-3′ (SEQ ID NO: 5), or functional variants thereof.
  • the ETS1 antagonist is an inorganic molecule.
  • An exemplary inorganic molecule that may be used as ETS1 antagonist is U0126.
  • the modulator compound is an miR-200a agonist.
  • a “miR-200a agonist” refers to a molecule which intensifies or mimics the biological activity of miR-200a, such as targeting and inhibiting UBASH3B.
  • miR-200a agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of miR-200a either by directly interacting with miR-200a or by acting on components of the biological pathway in which miR-200a participates.
  • Exemplary miR-200a agonists include miR-200a mimics.
  • the modulator compound is CBL agonist.
  • CBL agonist refers to a molecule which intensifies or mimics the biological activity of CBL.
  • CBL agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of CBL (for example, inactivation of EGFR) either by directly interacting with CBL or by acting on components of the biological pathway in which CBL participates.
  • Exemplary CBL agonists include CBL mimics.
  • the modulator compound is an EGFR antagonist.
  • An “EGFR antagonist” refers to a molecule (peptidyl or non-peptidyl) capable of neutralizing, blocking, inhibiting, abrogating or interfering with EGFR-associated activities such as its activation, signaling and its protein-tyrosine kinase activity, or abrogating the gene expression or protein level of EGFR.
  • the EGFR antagonist may reduce or inhibit, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, the expression level or biological activity of EGFR.
  • EGFR antagonists useful in the disclosed methods include peptidyl or non-peptidyl compounds that specifically bind EGFR, such as oligonucleotides, antibodies, and inorganic molecules.
  • oligonucleotides that can be used as EGFR antagonists include, but are not limited to, interfering ribonucleic acid (such as siRNA, shRNA and miRNA), protein nucleic acids (PNAs), and locked nucleic acids (LNAs).
  • the siRNA that can be used as EGFR antagonist may have a length of between about 10 to 50 nucleotides, or between about 15 to 50 nucleotides, or between about 20 to 50 nucleotides, or between about 25 to 50 nucleotides, or between about 30 to 50 nucleotides, or between about 35 to 50 nucleotides, or between about 40 to 50 nucleotides, or between about 10 to 45 nucleotides, or between about 10 to 40 nucleotides, or between about 10 to 35 nucleotides, or between about 10 to 30 nucleotides, or between about 10 to 25 nucleotides, or between about 10 to 20 nucleotides, or between about 15 to 50 nucleotides, or between about 15 to 35 nucleotides, or between about 15 to 30 nucleotides, or between about 15 to 25 nucleotides. In one embodiment, the siRNA has a length of between 15 to 30 nucleotides.
  • the EGFR antagonist is an antibody or small molecule which binds to EGFR.
  • the EGFR antagonist is an EGFR-targeted drug.
  • an EGFR antagonist has a binding affinity (dissociation constant) to EGFR of about 1,000 nM or less, of about 100 nM or less, or about 50 nM or less.
  • an EGFR antagonist inhibits EGFR signaling with an IC 50 of about 1,000 nM or less, of about 500 nM or less, or of about 50 nM or less.
  • the EGFR antagonist reduces or inhibits, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, the expression level or biological activity of EGFR.
  • EGFR-targeted drug refers to a therapeutic agent that binds to EGFR and reduces or inhibits EGFR activation.
  • agents include antibodies (such as Cetuximab, Matuzumab, and the like) and small molecules that bind to EGFR (such as Erlotinib, Gefitinib, CI-1033, GW-2016, Iressa (ZD-1839), Tarceva (OSI-774), PKI-166, EKB-569, HKI-272, and the like).
  • Two or more of the disclosed modulator compounds may be administered in a combination therapy, optionally together with one or more chemotherapeutic agents.
  • the two or more disclosed modulator compounds, and optionally one or more chemotherapeutic agents may be administered concurrently, or sequentially in any order, in the same or separate formulation.
  • Concurrent administration refers to administration of two or more modulator compounds, and optionally one or more chemotherapeutic agents, where at least part of the administration overlaps in time. Accordingly, concurrent administration includes a dosing regimen when the administration of one or more compound(s) continues after discontinuing the administration of one or more other compound(s).
  • “Sequential” administration refers to administration of two or more modulator compounds and optionally one or more chemotherapeutic agents, wherein a first compound or agent can occur prior to, and/or following, administration of a second compound or agent.
  • Combinations of the disclosed modulator compounds may be synergistic.
  • the disclosed modulator compounds may be used alone, or in combination with one or more other disclosed modulator compounds, or optionally in combination with one or more chemotherapeutic agents as part of a specific treatment regimen intended to provide a beneficial effect from the combined activity of these compounds.
  • the beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of modulator compounds and optionally, chemotherapeutic agents.
  • anti-cancer therapy refers to therapy useful in treating cancer, that may be used alone or in combination with other treatments.
  • anti-cancer therapeutic agents include, but are not limited to, chemotherapeutic agents, growth inhibitory agents, cytotoxic agents, agents used in radiation therapy, anti-angiogenesis agents, apoptotic agents, and the like.
  • chemotherapeutic agents include but are not limited to Abraxane, Amsacrine, Azacitidine, Bendamustine, Bleomycin, Busulfan, Cabazitaxel, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crisantaspase, Cyclophosphamide, Cytarabine, dacarbazine, Dactinomycin, Daunorubicin, Docetaxel, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Hydroxycarbamide, Idarubicin, Ifosfamide, Irinotecan, Leucovorin, Lomustine, Melphalan, Mercaptopurine, Mesna, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Pentostatin, Pen
  • the chemotherapeutic agent is selected from the group consisting of Paclitaxel, Docetaxel, Gemcitabine, Capecitabine and Vinorelbine.
  • a pharmaceutical composition comprising a UBASH3B antagonist and a ETS1 antagonist.
  • a pharmaceutical composition comprising a UBASH3B antagonist and a miR-200a agonist.
  • a pharmaceutical composition comprising a UBASH3B antagonist and a CBL agonist.
  • a pharmaceutical composition comprising a UBASH3B antagonist and a EGFR antagonist.
  • a pharmaceutical composition comprising a UBASH3B antagonist, a ETS1 antagonist, and a miR-200a agonist.
  • a pharmaceutical composition comprising a UBASH3B antagonist, a ETS1 antagonist, a miR-200a agonist, and a CBL agonist. In one embodiment, there is provided a pharmaceutical composition comprising a UBASH3B antagonist, a ETS1 antagonist, a miR-200a agonist, and an EGFR antagonist. In one embodiment, there is provided a pharmaceutical composition comprising a UBASH3B antagonist, a ETS1 antagonist, a miR-200a agonist, a CBL agonist, and an EGFR antagonist.
  • the disclosed composition comprises one or more modulator compounds selected from the group consisting of a UBASH3B antagonist, a ETS1 antagonist, a miR-200a agonist, a CBL agonist, and a EFGR antagonist, and a chemotherapeutic agent.
  • the chemotherapeutic agent is Paclitaxel.
  • compositions may comprise one or more pharmaceutically acceptable carriers or excipients, in the form of lyophilized formulations or aqueous solutions.
  • Pharmaceutically acceptable carriers or excipients are generally nontoxic to recipients at the dosages and concentrations employed. Typically, the carrier(s) or excipient(s) will form from 10% to 99.9% by weight of the compositions.
  • excipient refers to a pharmaceutically acceptable additive, other than the active ingredient, included in a formulation and having different purposes depending, for example, on the nature of the drug, and the mode of administration.
  • excipients include, but are not limited to, carriers; co-solvents, stabilizing agents, solubilizing agents and surfactants, buffers, antioxidants, tonicity agents, bulking agents, lubricating agents, emulsifiers, suspending or viscosity agents, antibacterial agents, chelating agents, preservatives, sweeteners, perfuming agents, flavoring agents, administration aids, and combinations thereof.
  • Some of the excipients or additives may have more than one possible function or use, depending on their properties and the nature of the formulation. Such excipients are generally formulated according to a number of factors well within the purview of those of ordinary skill in the art.
  • the term “pharmaceutically acceptable carrier” refers to media generally accepted in the art for the delivery of biologically active agents, i.e. the disclosed modulator compound alone or in combination with any of the other disclosed modulator compounds or anti-cancer therapeutic agents, to mammals, for example humans.
  • Such carriers are generally formulated according to a number of factors well within the purview of those of ordinary skill in the art. These include, without limitation, the type and nature of the active agent being formulated; the subject to which the agent-containing composition is to be administered; the intended route of administration of the composition; and the therapeutic indication being targeted.
  • Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms.
  • Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, for example, for stabilization of the active agent, well known to those of ordinary skill in the art.
  • pharmaceutically acceptable carriers are hyaluronic acid and salts thereof, and microspheres (including, but not limited to, poly(D,L)-lactide-co-glycolic acid copolymer (PLGA), poly(L-lactic acid) (PLA), poly(caprolactone) (PCL) and bovine serum albumin (BSA)).
  • the disclosed modulator compounds may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • macroemulsions for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • sustained-release preparations may also be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the modulator compound, which matrices are in the form of shaped articles, for example films, or microcapsules.
  • the formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished using methods known in the art, such as filtration through sterile filtration membranes.
  • the disclosed modulator compounds may be used in the methods as disclosed herein for the treatment of cancer.
  • the modulator compounds may be used alone, or in combination with one or more other modulator compounds, or in combination with one or more anti-cancer agents, such as chemotherapeutic agents.
  • a method of treating cancer by modulating expression of the UBASH3B gene, or the activity of the UBASH3B protein or a functional variant thereof comprises inhibiting expression of the UBASH3B gene, or the activity of the UBASH3B protein or a functional variant thereof. In one embodiment, the method comprises inhibiting expression of the UBASH3B gene, or the activity of the UBASH3B protein or a functional variant thereof by administering a UBASH3B antagonist, such as a UBASH3B inhibitor.
  • a method of sensitizing and/or re-sensitizing a cancer patient to a treatment with one or more chemotherapeutic agents by modulating expression of the UBASH3B gene, or the activity of the UBASH3B protein or a functional variant thereof comprises inhibiting expression of the UBASH3B gene, or the activity of the UBASH3B protein or a functional variant thereof. In one embodiment, the method comprises inhibiting expression of the UBASH3B gene, or the activity of the UBASH3B protein or a functional variant thereof by administering a UBASH3B antagonist, such as a UBASH3B inhibitor.
  • a use of the disclosed pharmaceutical composition and/or one or more disclosed modulator compounds e.g. the disclosed UBASH3B antagonist, ETS1 antagonist, miR200a agonist, CBL agonist, or EGFR antagonist
  • the disclosed pharmaceutical composition and/or one or more disclosed modulator compounds e.g. the disclosed UBASH3B antagonist, ETS1 antagonist, miR200a agonist, CBL agonist, or EGFR antagonist
  • one or more anti-cancer agents such as chemotherapeutic agents.
  • expression refers interchangeably to expression of a gene or gene product, including the encoded protein. “Expression” of a gene may refer to transcription into a polynucleotide, translation into a protein, or even post-translational modification of the protein.
  • inhibitor refers to the ability to cause an overall decrease of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or greater. “Inhibit” can refer to the symptoms of the disorder being treated, the presence or size of the tumor metastases, or the size of the primary tumor.
  • the expression of UBASH3B gene or the activity of the UBASH3B protein or a functional variant thereof may be inhibited by administering a UBASH3B antagonist, a ETS1 antagonist, and/or a miR-200a agonist.
  • the cancer is of an invasive and/or metastatic phenotype.
  • the treatment method comprises preventing cancer invasion and/or metastasis.
  • cancer invasion is meant the cancer cells breaking into the surrounding tissue and expanding the lesion.
  • An invasive form of cancer may also be known as a basal-type cancer, for example, a basal-type breast cancer or ovarian cancer.
  • a non-invasive form of cancer may also be known as a luminal-type cancer, for example a non-TNBC.
  • cancer is meant the spread of cancer from its primary site to other parts in the body. Cancer cells can break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through, the bloodstream, stop at a distant site in normal tissues elsewhere in the body and grow to form a life-threatening mass at the new site.
  • primary tumor or “primary cancer” is meant the original cancer and not a metastatic lesion located in another tissue, organ, or location in the subject's body. Metastasis can be local or distant.
  • Treatment includes any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever.
  • treatment includes prophylactic and therapeutic treatment.
  • Those in need of treatment include those already having a benign, pre-cancerous, or non-metastatic tumor as well as those in which the occurrence or recurrence of cancer is to be prevented.
  • Those in need of treatment also includes those who have previously been treated with one or more anti-cancer therapy, such as chemotherapy.
  • the term “sensitizing” refers to a process of rendering a subject receptive to a treatment. “Re-sensitizing” refers to a process of restoring responsiveness to a treatment in a subject who was receptive to a treatment but who is no longer receptive to a treatment due to the fact that the patient or the tumor cells of the patient developed a resistance against the anti-cancer therapy used for treating the cancer.
  • cancer and “cancerous” refer to or describe the physiological condition that is typically characterized by unregulated cell growth.
  • the cancer may be benign and/or malignant.
  • cancer examples include, but are not limited to, carcinoma, lymphoma, blastoma (including medulloblastoma and retinoblastoma), sarcoma (including liposarcoma and synovial cell sarcoma), neuroendocrine tumors (including carcinoid tumors, gastrinoma, and islet cell cancer), mesothelioma, schwannoma (including acoustic neuroma), meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies.
  • carcinoma including lymphoma, blastoma (including medulloblastoma and retinoblastoma)
  • sarcoma including liposarcoma and synovial cell sarcoma
  • neuroendocrine tumors including carcinoid tumors, gastrinoma, and islet cell cancer
  • mesothelioma including schwannoma (including a
  • breast cancer including invasive or metastatic breast cancer, such as TNBC
  • prostate cancer including invasive or metastatic prostate cancer
  • lung cancer including small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung and squamous carcinoma of the lung
  • colorectal cancer brain cancer, kidney or renal cancer, pancreatic cancer, gastric carcinoma, bladder cancer, esophageal cancer, mesothelioma, melanoma, thyroid cancer, head and neck cancer, osteosarcoma, glioblastoma, squamous cell cancer (such as epithelial squamous cell cancer), cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer), cervical cancer, ovarian cancer, liver cancer, hepatoma, rectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, vulval cancer, hepatic carcinoma, anal carcinoma, penile
  • the cancer is metastatic triple-negative breast cancer (TNBC), including any histologically confirmed triple-negative (ER-, PR-, Her2-) adenocarcinoma of the breast with locally recurrent or metastatic disease, for example, where the locally recurrent disease is not amenable to resection with curative intent.
  • TNBC metastatic triple-negative breast cancer
  • the cancer is invasive prostate cancer.
  • the cancer is invasive colon cancer.
  • subject includes human or other mammal and includes any individual it is desired to examine or treat using the disclosed methods. Patients are also included herein. However, it will be understood that “patient” does not imply that symptoms are present. Suitable mammals include, but are not restricted to, primates, livestock animals (e.g. sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g. rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g. cats, dogs) and captive wild animals (e.g. foxes, deer, dingoes). Preferably, the mammal is human.
  • livestock animals e.g. sheep, cows, horses, donkeys, pigs
  • laboratory test animals e.g. rabbits, mice, rats, guinea pigs, hamsters
  • companion animals e.g. cats, dogs
  • captive wild animals e.g. foxes, deer, dingoes.
  • the mammal is human.
  • a method of treating cancer, and/or sensitizing and/or re-sensitizing a cancer patient to a treatment with one or more chemotherapeutic agents by administering a modulator compound that inhibits expression of the UBASH3B gene, or the activity of the UBASH3B protein or a functional variant thereof.
  • the modulator compound, or a pharmaceutical composition thereof may be administered by any suitable means, such as by oral, parenteral (including intramuscular, intravenous, intraarterial, intraperitoneal, and subcutaneous), transdermal, intrapulmonary, or intranasal administration.
  • the modulator compound, or a pharmaceutical composition thereof may be administered according to various dosing schedules known to those skilled in the art including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion.
  • the modulator compound, or a pharmaceutical composition thereof, may be administered in a therapeutically effective amount.
  • therapeutically effective amount refers to an amount of a modulator compound to treat or prevent a disease or disorder in a mammal, or to provide the desired therapeutic effect.
  • the therapeutically effective amount of the modulator compound may reduce the number of cancer cells; reduce the primary tumor size; inhibit (i.e. slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e. slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the disorder.
  • the exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered, the mode of administration, the scheduling of administration, and other factors known to medical practitioners. Thus, it is not possible to specify an exact “effective amount”. However, for any given case, an appropriate “effective amount” may be determined by one of ordinary skill in the art using routine experimentation.
  • a modulator compound as disclosed herein may be administered to the patient, for example, by one or more separate administrations, or by continuous infusion.
  • a typical daily dosage might range from about 1 ⁇ g/kg to about 500 mg/kg or more, depending on the factors discussed above.
  • an EGFR antagonist such as Erlotinib
  • about 1 mg/kg, about 10 mg/kg, about 100 mg/kg, about 200 mg/kg, about 300 mg/kg, about 400 mg/kg, about 500 mg/kg, or more of an EGFR antagonist (such as Erlotinib) is administered. In one embodiment, less than about 1 ⁇ g/kg of an EGFR antagonist (such as Erlotinib) is administered. In one embodiment, about 1 nM to about 100 nM, about 5 nM to about 90 nM, about 10 nM to about 80 nM, about 15 nM to about 70 nM, about 30 nM to about 60 nM, or more of an UBASH3B antagonist or ETS1 antagonist may be administered.
  • about 5 nM, about 10 nM, about 20 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, or about 100 nM of an UBASH3B antagonist or ETS1 antagonist may be administered.
  • the treatment may be sustained until the cancer is treated, as measured by the methods described herein or known in the art.
  • Other dosage regimens that may be useful are also contemplated herein.
  • the modulator compound may be administered once every week, every two weeks, or every three weeks, at a dosage range as disclosed.
  • the progress of the therapy using the disclosed methods may be monitored by conventional techniques and assays, as well as the methods described herein.
  • maintenance doses may also be administered to reduce the likelihood of disease recurrence or progression.
  • a “maintenance” dose refers to one or more doses of a therapeutic agent (such as one or more of the disclosed modulator compounds) administered to the patient over or after a treatment period.
  • the maintenance doses may be administered at spaced treatment intervals, such as approximately every week, approximately every 2 weeks, approximately every 3 weeks, or approximately every 4 weeks, and may be provided for any length of time, including extended time periods up to the life-span of the subject. Maintenance therapy may be provided after initial therapy or in conjunction with initial or additional therapies.
  • the disclosed methods are capable of producing anti-cancer effects in a human patient without causing significant toxicities or adverse effects, so that the patient benefited from the treatment overall.
  • the efficacy of the disclosed treatment methods can be measured by various endpoints commonly used in evaluating cancer treatments, including but not limited to, duration of survival, tumor regression, tumor weight or size shrinkage, time to progression, progression free survival, overall response rate, duration of response, and quality of life, as discussed below.
  • the disclosed modulator compounds and compositions thereof may cause inhibition of metastatic spread without shrinkage of the primary tumor, or may simply exert a tumouristatic effect.
  • “Survival” refers to the patient remaining alive, and may refer to overall survival (OS), progression free survival (PFS), both. “Overall survival” (OS) refers to the patient remaining alive for a defined period of time, such as 1 year, 5 years, etc from the time of diagnosis or treatment. “Progression free survival” (PFS) refers to the patient remaining alive, without the cancer progressing or getting worse. By “extending survival” is meant increasing overall or progression free survival, for example in a treated patient relative to an untreated patient (i.e. relative to a patient not treated with a disclosed modulator compound or pharmaceutical composition thereof), and/or relative to a control treatment protocol, such as treatment only with a chemotherapeutic agent, such as those used in the treatment for breast cancer.
  • OS overall survival
  • PFS progression free survival
  • extending survival is meant increasing overall or progression free survival, for example in a treated patient relative to an untreated patient (i.e. relative to a patient not treated with a disclosed modulator compound or pharmaceutical composition thereof), and/or relative to
  • Survival is monitored for at least about one month, two months, four months, six months, nine months, or at least about 1 year, or at least about 2 years, or at least about 3 years, or at least about 4 years, or at least about 5 years, or at least about 10 years, etc., following the initiation of treatment or following the initial diagnosis.
  • Time to disease progression refers to the time, generally measured in weeks or months, from the time of initial treatment (e.g. with a disclosed modulator compound or pharmaceutical composition thereof), until the cancer progresses or worsens. Such progression can be evaluated by the skilled clinician. In the case of triple-negative breast cancer, for instance, progression can be evaluated by RECIST.
  • extending TTP is meant increasing the time to disease progression in a treated patient relative to an untreated patient (i.e. relative to a patient not treated with a disclosed modulator compound or pharmaceutical composition thereof), and/or relative to a patient treated with an approved anti-cancer drug.
  • the subject Prior to and/or during and/or after therapy using the disclosed methods, the subject may be subjected to a diagnostic or prognostic test as disclosed herein.
  • the subject's cancer expresses UBASH3B.
  • the UBASH3B gene or protein may be used as a biomarker for determining cancer patient prognosis (e.g. for response to treatment), or susceptibility to treatment (e.g. with an EGFR antagonist or a chemotherapeutic agent).
  • biomarker refers generally to a molecule, including a gene, mRNA, protein, carbohydrate structure, or glycolipid, the expression of which in or on a tissue or cell or secreted can be detected by known methods (or methods disclosed herein) and is predictive or can be used to predict (or aid prediction) for a cell, tissue, or patient's responsiveness and/or susceptibility to treatment regimes.
  • Any one or more of the UBASH3B, ETS1, miR-200a, CBL and EGFR genes or proteins disclosed herein may be used as a biomarker to determine a patient's responsiveness and/or susceptibility to a treatment method as disclosed herein.
  • the biomarker is UBASH3B.
  • the subject's cancer overexpresses UBASH3B.
  • overexpression is meant expression of a gene (or its product) at a level that is higher than the level of the gene (or its product) expressed under control conditions, for example in a normal subject (i.e. a subject not having cancer) or in a subject having a non-invasive and/or non-metastatic form of cancer.
  • level of expression or “expression level” are used interchangeably and refer to the amount of a polynucleotide, mRNA, or an amino acid product or protein in a biological sample.
  • the expression level or amount of a biomarker can be assessed and used to determine the response and/or susceptibility to treatment with the disclosed modulator compounds or pharmaceutical compositions thereof. These can be measured by methods known to those skilled in the art and also disclosed herein.
  • the amount or level of biomarker is determined using IHC (e.g. of patient tumor sample).
  • the level of expression refers to the amount of a protein in a biological sample as determined using IHC.
  • Information on expression level of the one or more biomarkers may be used to inform a treatment decision, to constitute information provided on a package insert, or to provide marketing/promotional guidance etc.
  • a patient's cancer having a higher level of UBASH3B gene expression or UBASH3B protein activity relative to the level of UBASH3B gene expression or UBASH3B protein activity in a normal subject (i.e. a subject not having cancer) or in a subject having a non-invasive and/or non-metastatic form of cancer indicates that the patient may have decreased survival or may be suitable for treatment with a disclosed modulator compound (e.g. a UBASH3B antagonist, or an EGFR antagonist) or a pharmaceutical composition thereof.
  • a disclosed modulator compound e.g. a UBASH3B antagonist, or an EGFR antagonist
  • a patient's cancer having a lower, or the same level of UBASH3B gene expression or UBASH3B protein activity relative to the level of UBASH3B gene expression or UBASH3B protein activity in a normal subject (i.e. a subject not having cancer) or in a subject having a non-invasive and/or non-metastatic form of cancer indicates that the patient may have increased survival or may not be suitable for treatment with a disclosed modulator compound (e.g. a UBASH3B antagonist, or an EGFR antagonist) or a pharmaceutical composition thereof.
  • a disclosed modulator compound e.g. a UBASH3B antagonist, or an EGFR antagonist
  • treatment with an anti-cancer therapy other than the disclosed modulator compounds or pharmaceutical compositions thereof may be preferable.
  • a method of determining cancer patient comprising the steps of: determining the level of UBASH3B gene expression or UBASH3B protein activity in the patient's cancer (for example, using a technique known in the art or disclosed herein), and classifying the patient as having decreased survival if the patient's cancer has a higher level of UBASH3B gene expression or UBASH3B protein activity relative to the level of UBASH3B gene expression or UBASH3B protein activity in a non-invasive cancer.
  • determining cancer patient e.g. TNBC, prostate cancer, colon cancer
  • a method of determining cancer patient comprising the steps of: determining the level of UBASH3B gene expression or UBASH3B protein activity in the patient's cancer (for example, using a technique known in the art or disclosed herein), and classifying the patient as having decreased survival if the patient's cancer has a higher level of UBASH3B gene expression or UBASH3B protein activity relative to the level of UBASH3B gene expression or UBASH3B protein activity in a normal subject.
  • higher UBASH3 gene expression or UBASH3B protein activity indicates likelihood of decreased OS and/or PFS compared to a patient whose cancer has lower UBASH3 gene expression or UBASH3B protein activity.
  • higher UBASH3B, biomarker expression indicates increased OS and/or PFS when the patient is treated with a disclosed modulator compound (e.g. UBASH3B antagonist, or EFGR antagonist) or a pharmaceutical composition thereof.
  • lower UBASH3B biomarker expression indicates decreased OS and/or PFS, or no improvement in OS and/or PFS when the patient is treated with a disclosed modulator compound (e.g. UBASH3B antagonist, or EFGR antagonist) or a pharmaceutical composition thereof.
  • the cancer is TNBC, and higher UBASH3B biomarker expression indicates increased OS and/or PS when the patient is treated with a disclosed modulator compound (e.g. UBASH3B antagonist, or EFGR antagonist) or a pharmaceutical composition thereof.
  • a disclosed modulator compound e.g. UBASH3B antagonist, or EFGR antagonist
  • the cancer is TNBC, and lower UBASH3B biomarker expression indicates decreased OS and/or PFS, or no improvement in OS and/or PFS when the patient is treated with a disclosed modulator compound (e.g. UBASH3B antagonist, or EFGR antagonist) or a pharmaceutical composition thereof.
  • the cancer is invasive prostate cancer
  • lower UBASH3B biomarker expression indicates decreased OS and/or PFS, or no improvement in OS and/or PFS when the patient is treated with a disclosed modulator compound (e.g. UBASH3B antagonist, or EFGR antagonist) or a pharmaceutical composition thereof.
  • a disclosed modulator compound e.g. UBASH3B antagonist, or EFGR antagonist
  • a high UBASH3B biomarker expression may refer to 50% or more of the tumor cells with moderate UBASH3B staining intensity, combined moderate/high UBASH3B staining intensity or high UBASH3B staining intensity, wherein UBASH3B expression is detected using an antibody, wherein the UBASH3B biomarker expression indicates that the patient is likely to have increased OS and/or PFS when the patient is treated with a disclosed modulator compound (e.g. UBASH3B antagonist, or EFGR antagonist) or a pharmaceutical composition thereof.
  • a disclosed modulator compound e.g. UBASH3B antagonist, or EFGR antagonist
  • the amount of UBASH3B biomarker may be determined using a method comprising: (a) performing IHC analysis of a sample (such as a patient cancer sample) with anti-UBASH3B antibody; and b) determining expression of a UBASH3B biomarker in the sample.
  • IHC staining intensity is determined relative to a reference value.
  • UBASH3B biomarker expression is determined using a UBASH3B staining intensity scoring scheme as disclosed herein, for example from a value of 0 to 255.
  • the method further comprises stratifying the patients based on IHC score.
  • a sample for use in the disclosed methods may be obtained from a subject in need of therapy, and/or undergoing therapy, and/or has undergone therapy.
  • the sample may be obtained from the primary tumor or from a metastatic tumor.
  • the sample may be obtained when the cancer is first diagnosed or, for example, after the tumor has metastasized.
  • the tumor sample is of breast, prostate, colon, lung, lymph node, liver or brain.
  • the sample may be a tumor sample, or other biological sample, such as tissues, cells, body fluids and isolates thereof etc., isolated from the subject, as well as tissues, cells and fluids etc. present within the subject (i.e. the sample is in vivo).
  • samples include: whole blood, blood fluids (e.g. serum and plasma), lymph and cystic fluids, sputum, stool, tears, mucus, hair, skin, ascitic fluid, cystic fluid, urine, nipple exudates, nipple aspirates, sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, archival samples, explants and primary and/or transformed cell cultures derived from patient tissues etc.
  • the sample may be untreated, treated, diluted or concentrated from a subject.
  • the sample may be a “breast-associated” body fluid, which is a fluid which, when in the body of a patient, contacts or passes through breast cells or into which cells, nucleic acids or proteins shed from breast cells are capable of passing.
  • breast-associated body fluids include blood fluids, lymph, cystic fluid, and nipple aspirates.
  • the sample may be obtained at one or more time points. Expression levels of the marker(s) may optionally be compared with a control sample.
  • the control sample may be a sample derived from a person not having cancer, or a sample derived from a person having a non-invasive and/or non-metastatic form of cancer. One or more control samples may be employed.
  • the present invention also contemplates sample preparation methods in certain preferred embodiments.
  • the sample may be amplified by a variety of mechanisms, some of which may employ amplification techniques such as PCR (e.g. RT-PCR) and the ligase chain reaction (LCR) etc.
  • PCR e.g. RT-PCR
  • LCR ligase chain reaction
  • the disclosed method may be useful in selecting a therapy for a patient with cancer (e.g. TNBC, prostate cancer etc.) comprising determining expression of a UBASH3B biomarker in a sample from the patient, and selecting a cancer medicament based on the level of expression of the biomarker.
  • a therapy for a patient with cancer e.g. TNBC, prostate cancer etc.
  • a high level of the biomarker(s) (for example, higher level of expression relative to the expression of the biomarker in a normal subject or a cancer patient with a non-invasive or non-metastatic cancer) will result in selection of a disclosed modulator compound or a pharmaceutical composition thereof, for example a UBASH3B antagonist (such as a siRNA or shRNA as disclosed herein), or a EGFR antagonist (such as Erlotinib), for use in treating the patient.
  • a UBASH3B antagonist such as a siRNA or shRNA as disclosed herein
  • a EGFR antagonist such as Erlotinib
  • the patient will be selected for a treatment with an anti-cancer therapy other than a disclosed modulator compound or a pharmaceutical composition thereof, for example with a chemotherapeutic agent (e.g. Paclitaxel).
  • a chemotherapeutic agent e.g. Paclitaxel
  • the sample is of the patient's cancer (e.g. TNBC).
  • detection of a high level of UBASH3B biomarker indicates increased PFS and/or OS when the patient is treated with a UBASH3B antagonist (such as a siRNA or shRNA as disclosed herein), or a EGFR antagonist (such as Erlotinib).
  • detection of low UBASH3B biomarker indicates a decreased PFS and/or OS, or no improvement in OS and/or PFS when the patient is treated with a UBASH3B antagonist (such as a siRNA or shRNA as disclosed herein), or a EGFR antagonist (such as Erlotinib).
  • the cancer is TNBC.
  • RNA-Seq RNA-Seq
  • SAGE serial analysis of gene expression
  • MassARRAY technique FISH
  • Immunohistochemistry (IHC) methods can be used for detecting the expression levels of proteins in a sample.
  • the IHC methods may be a direct assay or an indirect assay.
  • the direct assay typically uses a labeled reagent, such as a fluorescent tag or an enzyme-labeled primary antibody, which can be visualized without further antibody interaction.
  • an unconjugated primary antibody is typically used to bind to the antigen and then a labeled secondary antibody is used which binds to the primary antibody.
  • a chromagenic or fluorogenic substrate may then be added to provide visualization of the antigen. Signal amplification occurs because several secondary antibodies may react with different epitopes on the primary antibody.
  • the primary and/or secondary antibody used for immunohistochemistry may be labeled with a detectable moiety.
  • labels include enzymes (such as peroxidase) that can catalyse a colour-producing reaction, fluorophores (such as fluorescein, rhodamine, rare earth chelates (europium chelates), Texas Red, dansyl, or commercially available fluorophores such SPECTRUM ORANGE®), and colloidal gold particles.
  • the tissue section may be exposed to primary antibody for a sufficient period of time and under suitable conditions such that the primary antibody binds to the target protein antigen in the tissue sample.
  • the extent of binding of antibody to the sample may determined by using any one of the detectable labels discussed above.
  • IHC may be combined with morphological staining, either prior to or thereafter.
  • the sections mounted on slides may be stained with a morphological stain, such as hematoxylin for evaluation.
  • the section may be stained with one or more dyes, each of which distinctly stains different cellular components.
  • staining may be optimized for a given tissue by increasing or decreasing the length of time the slides remain in the dye.
  • tissue section may be analyzed by standard techniques of microscopy.
  • Antibodies suitable for use in IHC are well known in the art and many suitable antibodies are commercially available. Automated systems for slide preparation and IHC processing are available commercially, for example the Ventana® BenchMark XT system. The staining density may then be determined, for example using commercially available software, and given a numerical value for statistical analysis.
  • Gene expression profiling or analysis include methods based on hybridization analysis of polynucleotides and methods based on sequencing of polynucleotides. Methods based on hybridization include Northern Blotting, in situ hybridization, RNAse protection assays, and polymerase chain reaction (PCR). Antibodies may also be employed that can recognize specific duplexes, including DNA, RNA, DNA-RNA hybrid and DNA-protein duplexes. Methods based on sequencing include Serial Analysis of Gene Expression (SAGE), and Massively Parallel Signature Sequencing (MPSS).
  • SAGE Serial Analysis of Gene Expression
  • MPSS Massively Parallel Signature Sequencing
  • PCR may be used to compare mRNA levels in different samples, for example in normal and cancerous (e.g. non-invasive, invasive or metastatic) tissues, and in samples with or without drug treatment.
  • the starting material for a PCR is typically total RNA isolated from a sample, such as human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively.
  • General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et ah, Current Protocols of Molecular Biology, John Wiley and Sons (1997).
  • the isolated RNA may then be reverse transcribed into cDNA using reverse transcriptases (e.g.
  • AMV-RT avilo myeloblastosis virus reverse transcriptase
  • MMLV-RT Moloney murine leukemia virus reverse transcriptase
  • specific primers random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling.
  • the derived cDNA can then be used as a template in the subsequent PCR reaction, using thermostable DNA-dependent DNA polymerases such as the Taq DNA polymerase, which has a 5′-3′ nuclease activity but lacks a 3′-5′ proofreading endonuclease activity.
  • Primers and probes used for PCR are designed based upon the sequences present in the gene to be amplified. Factors considered in PCR primer design include primer length, melting temperature (Tm), and G/C content, specificity, complementary primer sequences, and 3′-end sequence. Optimal PCR primers may be 17-30 bases in length, and may contain about 20-80%, such as, for example, about 50-60% G+C bases. Tm's of between 50 and 80° C., e.g. about 50 to 70° C., may be used.
  • qRT-PCR quantitative real time PCR
  • TAQMAN® probe a dual-labeled fluorigenic probe
  • qPCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700® Sequence Detection System® (Perkin-Elmer-Applied Biosystems, Foster City, Calif., USA) and CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, Calif.).
  • the system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD.
  • Fluorescence values are recorded during every PCR cycle and represent the amount of product amplified to that point in the amplification reaction.
  • the point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (Ct) value which is used to compare the level of gene expression between different samples, for example between a target and reference sample.
  • An internal standard for example a gene that is unaffected by the experimental treatment such as housekeeping genes like glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and P-actin
  • GPDH glyceraldehyde-3-phosphate-dehydrogenase
  • P-actin may be used to minimize errors and the effect of sample-to-sample variation.
  • RNA-Seq also called Whole Transcriptome Shotgun Sequencing (WTSS) refers to the use of high-throughput sequencing technologies to sequence cDNA to obtain information about a sample's RNA content.
  • RNA-Seq may be performed on a variety of platforms, such as using the Illumina Genome Analyzer platform (for example as described in Mortazavi A et al., Nature Methods 5(7): 621-628 (2008)), ABI Solid Sequencing (for example as described in Cloonan N et al., Nature Methods 5(7):613-619 (2008)), or Life Science's 454 Sequencing (for example as described in Barbazuk W B et al., The Plant Journal 51(5): 910-918 (2007)).
  • Illumina Genome Analyzer platform for example as described in Mortazavi A et al., Nature Methods 5(7): 621-628 (2008)
  • ABI Solid Sequencing for example as described in Cloonan N et al., Nature Methods 5(7):613-619 (2008)
  • RNA-Seq techniques that may be used are also described in Wang et al., Nature Reviews Genetics 10 (1):57-63 (January 2009); Ryan et al., BioTechniques 45 (1):81-94 (2008); and Maher et al., Nature 458(7234):97-101 (January 2009).
  • Differential gene expression can also be identified, or confirmed using microarrays, where polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest.
  • the source of mRNA may be total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines.
  • the chips are washed to remove non-specifically bound probes, and scanned by detection methods such as confocal laser microscopy or CCD camera. Quantitation of hybridization of each arrayed element enables assessment of corresponding mRNA abundance.
  • Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GENCHIPTM technology, or Incyte's microarray technology.
  • Serial analysis of gene expression may be used to simultaneously and quantitatively analyze a large number of gene transcripts, without the need of providing an individual hybridization probe for each transcript.
  • a short sequence tag (about 10-14 bp) is generated that contains sufficient information to uniquely identify a transcript.
  • Many transcripts are then linked together to form long serial molecules, that can be sequenced, revealing the identity of the multiple tags simultaneously.
  • the expression pattern of any population of transcripts can be quantitatively evaluated by determining the abundance of individual tags, and identifying the gene corresponding to each tag. For more details see, e.g. Velculescu et al., Science 270:484-487 (1995); and Velculescu et al., Cell 88:243-51 (1997).
  • MassARRAY (Sequenom, San Diego, Calif.) technology is an automated, high-throughput method of gene expression analysis using mass spectrometry (MS) for detection.
  • Isolated RNA is reverse transcribed and amplified (e.g. by PCR), and the cDNAs are subjected to primer extension.
  • the cDNA-derived primer extension products are purified, and dispensed on, a chip array that is pre-loaded with the components needed for MALDI-TOF MS sample preparation.
  • the various cDNAs present in the reaction are quantified by analyzing the peak areas in the mass spectrum obtained.
  • Fluorescence in situ hybridization enables visualization and mapping of genetic material in an individual's cells, including specific genes or portions of genes.
  • the chromosomes to be studied are first firmly attached to a substrate, such as a glass slide. Repetitive DNA sequences are then blocked by adding short fragments of DNA to the sample in order to reduce the occurrence of false positive signals.
  • Fluorescently labeled single stranded DNA probes that hybridize to the genes of interest are then applied to the chromosomal DNA and incubated for approximately 12 hours to allow the probes to hybridize to their respective targets. Unhybridized or partially hybridized probes are removed by washing and the probes are then visualized and quantified using fluorescence microscopy.
  • Proteomics which enables study of the global changes of protein expression in a sample (also referred to as “expression proteomics”), may be used to supplement the methods of gene profiling as disclosed herein.
  • Proteomics typically includes (1) separating individual proteins in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identifying the individual proteins recovered from the gel (for example, by mass spectrometry or N-terminal sequencing); and (3) analyzing the data using bioinformatics.
  • protein expression is quantified. Such protein analysis may be performed using IHC as described herein on patient tumor samples.
  • Antibodies e.g. monoclonal antibodies specific for each marker
  • antisera e.g. polyclonal antisera
  • the antibodies can be detected by direct labeling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as biotin, or an enzyme such as horse radish peroxidase or alkaline phosphatase.
  • unlabeled primary antibody is used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody.
  • IHC analysis may further comprise morphological staining, either prior to or after IHC analysis.
  • hematoxylin e.g. Hematoxylin II (Ventana)
  • a bluing reagent may be used following hematoxylin staining.
  • UBASH3B biomarker using IHC Detection of UBASH3B biomarker using IHC is disclosed herein, and a UBASH3B staining intensity scoring scheme with numerical values of 0 to 255 is disclosed herein.
  • amount of UBASH3B biomarker is determined using a method comprising: (a) performing gene expression profiling, PCR (such as rtPCR), RNA-seq, microarray analysis, SAGE, MassARRAY technique, or FISH on a sample (such as a patient cancer sample) with anti-UBASH3B antibody; and b) determining expression of a UBASH3B biomarker in the sample.
  • biomarkers may also be detected using the disclosed methods.
  • exemplary other biomarkers include EGFR, ETS1, miR-200a, and CBL.
  • the article of manufacture may comprise a container, a label and a package insert.
  • Suitable containers include, for example, bottles, vials, syringes, and the like, which may be made from a variety of materials such as glass or plastic.
  • the container may hold one or more disclosed modulator compounds and/or compositions thereof and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the label on, or associated with, the container may indicate that the composition is used for treating one or more types of cancer as discussed herein.
  • the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • the article of manufacture may comprise a package insert with instructions for use, including for example instructing the user of the disclosed modulator compound(s) or compositions thereof to administer the disclosed modulator compound(s) or compositions thereof, and optionally an anti-cancer drug, to a patient with cancer (e.g. breast cancer, prostate cancer, etc.). The patient may have previously been treated with one or more anti-cancer therapy for example, for TNBC or invasive prostate cancer.
  • the package insert may optionally contain some or all of the results found in the Examples as disclosed herein.
  • the disclosed modulator compound(s) or compositions thereof may also be packaged alone or in combination with other anti-cancer drugs as a kit.
  • the kit can include optional components that aid in the administration of the unit dose to patients, such as vials for reconstituting powder forms, syringes for injection, customized IV delivery systems, inhalers, etc.
  • the unit dose kit can contain instructions for preparation and administration of the compositions.
  • the instructions comprises instructions for use, including for example instructing the user of the composition to administer the disclosed modulator compound(s) or compositions thereof and an anti-cancer drug to a patient who has previously been treated, for example for breast cancer or prostate cancer.
  • the instructions may optionally contain some or all of the results found in the Examples disclosed herein.
  • the kit may be manufactured as a single use unit dose for one patient, multiple uses for a particular patient (at a constant dose or in which the individual compounds may vary in potency as therapy progresses); or the kit may contain multiple doses suitable for administration to multiple patients (“bulk packaging”).
  • the kit components may be assembled in cartons, blister packs, bottles, tubes, and the like.
  • FIG. 1 Use of Functional Genomics for Identification of the Overexpression of UBASH3B in TNBC and Association with Poor Disease Prognosis
  • FIG. 1( a ) is a heat map representation of 103 genes that expressed more than 2-fold higher in TNBC tissues and cell lines compared to non-TNBC breast cancer tissues and cell lines. Expressions of ER (ESR1) and its related genes FOXA1 and GATA3 as well as AR and PGR are also shown. 19 “druggable” genes are listed on the right. Genes in bold (PSAT1, B3GNT5, UBASH3B, AGPAT4, ACOT9, CDK6, HYAL3) showed association with poor metastasis-free survival.
  • FIG. 1( b ) shows representative images of MB231 cells cultured in 3D Matrigel on the left. The cells were depleted of the indicated genes using two independent siRNA sequences, siRNA#1 and siRNA#2. Knockdown efficiency was assessed by real-time PCR and is shown on the right.
  • FIG. 1( c ) shows real-time PCR and Western blot analysis of UBASH3B expression in a panel of breast cancer cell lines. *P ⁇ 0.05, unpaired two-tailed t-test.
  • FIG. 1( d ) depicts box plots showing the mRNA expression of UBASH3B in two Oncomine datasets, Waddell and TCGA breast.
  • FIG. 1( e ) show representative images of immunohistochemistry (IHC) staining of UBASH3B on paraffin-embedded breast cancer tissues from JWCI patient cohort. Staining was graded based on the intensity and P-value was calculated by Wilcoxon test.
  • IHC immunohistochemistry
  • FIG. 1( g ) shows Kaplan-Meier analyses of disease-specific survival of breast cancer patients of GSE12276 dataset. Patients whose tumors have expression of the UBASH3B higher than mean were labeled in light grey, and those with expression of this gene lower than mean were labeled in dark grey. P-values were calculated using Cox proportional hazards regression model, Wald test. Error bars, mean+SEM.
  • FIG. 1( h ) depicts a Venn diagram showing the overlap of genes overexpressed in TNBC tissues and cell lines.
  • FIG. 1( i ) shows Kaplan-Meier analyses of disease-specific survival of breast cancer patients of the indicated published datasets. Patients whose tumors have expression of the gene higher than the mean were labeled in light grey, and those with expression of the gene lower than the mean were labeled in dark grey. P-values were calculated using Cox proportional hazards regression model, Wald test.
  • FIG. 1( j ) shows the real-time PCR analysis of UBASH3A in a panel of breast cancer cell lines.
  • FIG. 1( k ) shows the real-time PCR and Western blot analysis of UBASH3B expression in a panel of prostate cancer cell lines. *P ⁇ 0.05, unpaired two-tailed t-test.
  • FIG. 1( l ) depicts box plots showing the mRNA expression of UBASH3B in an Oncomine prostate cancer dataset. Error bars, mean+SEM.
  • FIG. 2 Shows that UBASH3B is a Transcriptional Target of ETS1
  • FIG. 2( a ) shows a schematic diagram of UBASH3B gene structure. TSS, Transcription start site.
  • FIG. 2( b ) shows real-time PCR and Western blot analysis of ETS1 expression in a panel of breast cancer cell lines. *P ⁇ 0.05, unpaired two-tailed t-test.
  • FIG. 2( c ) shows the results of ChIP assay of ETS1 on the promoter of UBASH3B. 8 primer pairs were designed ⁇ 2000 bp flanking TSS. Quantification of binding was assessed by real-time PCR and represented as percent input.
  • FIG. 2( d ) shows real-time PCR and Western blot analysis of UBASH3B expression after ETS1 depletion in BT549. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 2( e ) shows real-time PCR analysis of UBASH3B in MB231 upon treatment of 5 ⁇ M of U0126 for the indicated time points. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 2( f ) depicts a dot plot showing the positive correlation of ETS1 and UBASH3B mRNA expression in patient tissues from the GSE12276 dataset on the left.
  • a bar chart representation of the proportion of patients with the expression of UBASH3B and ETS1 higher than (dark grey) or lower than (light grey) the mean expression in GSE12276 dataset is shown on the right.
  • P-values were calculated using two sided Fisher's exact test.
  • FIG. 2( g ) shows Kaplan-Meier analysis of disease-specific survival of breast cancer patients of GSE12276 dataset. Patients whose tumors, have expression of ETS1 higher than mean were labeled in light grey, and those with underexpression of this gene lower than median were labeled in dark grey. P-values were calculated using Cox proportional hazards regression model, Wald test. Error bars, mean+SEM.
  • FIG. 2( h ) depicts box plots showing the mRNA expression of ETS1 in JWCI breast cancer tissue samples based on gene-expression profiling. P-values were calculated by unpaired two-tailed t-test.
  • FIG. 2( i ) depicts box plots showing the mRNA expression of ETS1 in two Oncomine datasets, Waddell and TCGA breast.
  • FIG. 2( j ) shows real-time PCR and Western blot analysis of UBASH3B expression after ETS1 depletion in DU145 and PC3. *P ⁇ 0.05, paired two-tailed t-test. Error bars, mean+SEM.
  • FIG. 3 Shows that UBASH3B is a Target of miR200a, and MiR200s are Associated with Non-TNBC Status but Only miR200a Regulates UBASH3B Expression
  • FIG. 3( a ) shows a schematic diagram of UBASH3B gene structure.
  • TAA Stop codon
  • 3′ UTR 3′-untranslated region
  • MRE miRNA response element
  • FIG. 3( b ) shows real-time PCR analysis of miR200a expression in a panel of breast cancer cell lines. *P ⁇ 0.05, unpaired two-tailed t-test.
  • FIG. 3( c ) depicts a schematic diagram showing the four miRNA response element (MRE) (SEQ ID NO:43-46) in the 3′UTR of the UBASH3B gene base-paired to miR200a mature sequence (SEQ ID NO: 47).
  • MRE miRNA response element
  • Two regions (P1 and P2) were cloned into a luciferase reporter pMIR-REPORT.
  • P1 mut and P2 mut were constructed by mutating the MRE to the mutant sequence (SEQ ID NO: 48) as indicated (left).
  • Luciferase reporter assay in cells co-transfected with miR200a or miR200c mimics and pMIR-REPORT containing wild-type or mutant P1 or P2 is shown on the right. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 3( d ) shows real-time PCR and Western blot analysis of UBASH3B expression in MB231 and BT549 overexpressing miR200a or miR200c mimics. Protein expression of ZEB1 and ZEB2 were also assessed. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 3( e ) shows real-time PCR and Western blot analysis of UBASH3B expression in the indicated cells transfected with miR200a antagomir. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 3( f ) shows real-time PCR and Western blot analysis of UBASH3B expression in the indicated cells transfected with miR200a mimics and/or ETS1 siRNA. *P ⁇ 0.05, paired two-tailed t-test. Error bars, mean+SEM.
  • FIG. 3( g ) shows real-time PCR analysis of miR200b/c in a panel of breast cancer cell lines. *P ⁇ 0.05, unpaired two-tailed t-test.
  • FIG. 3( h ) depicts box plots showing the miR200a/b/c expression assessed by RT-qPCR in breast cancer specimens. P-values were calculated by unpaired two-tailed t-test.
  • FIG. 3( i ) shows real-time PCR of UBASH3B expression in DU145 and PC3 prostate cancer lines overexpressing miR200a or miR200c mimics. *P ⁇ 0.05, paired two-tailed t-test. Error bars, mean+/ ⁇ SEM.
  • FIG. 4 Shows UBASH3B Knockdown Reduces Malignancy and Therapeutic Response to Erlotinib, and UBASH3B Depletion Reduces Cancer Cell Aggressiveness
  • FIG. 4( a ) shows the results of Transwell Matrigel invasion assay conducted on MB231 and BT549 depleted of UBASH3B using two independent siRNAs in the presence or absence of EGF as a chemoattractant (top). EGFR and UBASH3B expression was assessed by Western blot analysis (bottom). *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 4( b ) shows contingency analysis of UBASH3B and EGFR IHC staining on 73 breast cancer tissues from JWCI patient cohort. P-value was calculated using Fisher's exact test.
  • FIG. 4( c ) shows UBASH3B expression assessed by Western blot analysis (left). Representative images of indicated cells grown in 3D Matrigel are shown on the right.
  • FIG. 4( d ) shows Western blot analysis of EGFR and UBASH3B expression on the left, and the results of transwell invasion assay on the right using MB231-LN cells with UBASH3B depletion and EGFR overexpression. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 4( e ) shows the results of methylcellulose assay of MB231-LN stable knockdown cells in response to Erlotinib with the indicated concentrations.
  • FIG. 4( g ) shows the EC50 of MB231-LN stable cell lines towards Erlotinib as assessed by methylcellulose assay. *P ⁇ 0.05, paired two-tailed t-test. Error bars, mean+SEM.
  • FIG. 4( h ) shows the results of transwell matrigel invasion assay on DU145 and PC3 prostate cancer lines in the presence of EGF as a chemoattractant (top). *P ⁇ 0.05, paired two-tailed t-test. UBASH3B knockdown efficiency was assessed by Western blotting (bottom).
  • FIG. 4( i ) shows the results of transwell matrigel invasion assay conducted on MB231 cells with stable overexpression of UBASH3B followed by the depletion of endogeneous UBASH3B using 3′UTR siRNA. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 4( j ) shows Western blot analysis of EGFR and UBASH3B expression in normal immortalized breast cell line, MCF10A.
  • FIG. 4( k ) shows the results of tumorsphere assay of MB231 depleted of UBASH3B using two independent siRNAs. *P ⁇ 0.05, paired two-tailed t-test. Representative images of the tumorspheres are shown.
  • FIG. 4( l ) shows the results of tumorsphere assay on DU145 and PC3 depleted of UBASH3B. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 4( m ) shows the results of cell viability assay on MB231, BT549, DU145, and PC3 depleted with UBASH3B.
  • FIG. 4( n ) shows the results of 3D Matrigel assay using MB231-LN cells with UBASH3B depletion and EGFR overexpression.
  • FIG. 4( o ) shows the results of tumorsphere assay using MB231-LN cells with UBASH3B depletion and EGFR overexpression. *P ⁇ 0.05, paired two-tailed t-test. Error bars, mean+SEM.
  • FIG. 5 Shows that UBASH3B Knockdown Reduces Breast Cancer Metastasis, and UBASH3B Depletion Sensitizes TNBC Cells to Paclitaxel.
  • FIG. 5( a ) shows the Western Blot on UBASH3B knockdown by shRNAs in LM2 cells.
  • FIG. 5( c ) shows representative BLI images of mice of (b), at 4 wks post injection.
  • FIG. 5( d ) shows whole lung images of mice from a repeat experiment as (b), at 4 wks post injection.
  • FIG. 5( f ) shows the Western Blot on UBASH3B knockdown by shRNA in 4T1 cells.
  • FIG. 5( h ) shows representative gross images of lung metastasis from mice as in (g).
  • FIG. 5( j ) shows representative gross images of spontaneous lung metastasis from mice as (i).
  • FIG. 5( k ) shows lung metastasis of MB231-LN cells of control (NC) or shUBASH3B (KD), with ectopic expression of vector or EGFR.
  • FIG. 5( l ) shows the results of methylcellulose assay of MB231-LN stable knockdown cells in response to Paclitaxel with indicated concentrations.
  • FIG. 5( m ) shows the results of real-time PCR and Western blot analysis of UBASH3B expression in SUM159PT parental and Paclitaxel-resistant (SUM159PT-R) cell lines.
  • FIG. 5( n ) shows depletion of UBASH3B in SUM159PT and SUM159PT-R cell lines using two independent siRNA followed by treatment of Paclitaxel in a range of dosages for 72 hrs.
  • Cell viability assay was performed and EC50 of Paclitaxel in each sample was determined and shown at the top.
  • UBASH3B knockdown efficiency was assessed by Western blotting, shown at the bottom. *P ⁇ 0.05, paired two-tailed t-test. Error bars, mean+SEM.
  • FIG. 6 Shows that the Oncogenic Role of UBASH3B Requires Phosphatase Activity Targeting CBL Phosphorylation and EGFR Degradation
  • FIG. 6( a ) shows Matrigel invasion of cells expressing wild-type (WT) or mutant UBASH3B (H391A) in the presence or absence of EGF as chemoattractant. *P ⁇ 0.05, paired two-tailed t-test.
  • FIG. 6( b ) shows EGFR and UBASH3B expression assessed by Western blot analysis.
  • FIG. 6( d ) shows the results of co-immunoprecipitation assay conducted on HEK293T with transient expression of CBL and wild-type (WT) or mutant UBASH3B in the presence or absence of EGF.
  • FIG. 6( e ) shows the results of co-immunoprecipitation assay conducted on BT549 stably expressing wild-type (WT) or mutant UBASH3B in the presence or absence of EGF.
  • FIG. 6( f ) shows western blot analysis of EGFR, UBASH3B, and CBL protein expression in BT549 depleted with UBASH3B and/or CBL.
  • FIG. 6( g ) depicts a mechanistic model showing that the expression of UBASH3B is positively regulated by ETS1 and negatively regulated by miR200a, which results in the overexpression of UBASH3B in the aggressive cancer cells.
  • the overexpressed UBASH3B in turn dephosphorylates CBL, which would otherwise degrade EGFR-protein.
  • the high level of EGFR protein would in turn promote the invasiveness of the cancer cells. Error bars, mean+SEM.
  • Non-limiting examples of the invention including the best mode, and a comparative example will be further described in greater detail by reference to specific Examples, which should not be construed as in any way limiting the scope of the invention.
  • the cancer subtype-specific gene expression analysis was performed on Waddell, TCGA breast cancer datasets and Varambally prostate cancer dataset using Oncomine.
  • Gene expression profiling was performed on a panel of breast cancer cell lines purchased from ATCC and primary breast tumor specimens were obtained from John Wayne Cancer Institute (JWCI, Santa Monica, Calif. USA), which were obtained using protocols approved by the Institutional Review Board of the National University of Singapore (NUS-IRB); informed consent was obtained from each individual who provided the tissues.
  • the survival analysis was performed on breast cancer datasets from GSE12276, GSE1456, and GSE2034 with relevant clinical information as previously described 1-3 .
  • Breast cancer patients were classified into groups with higher or lower expression of the indicated genes based on the mean value of the gene expression.
  • the survival association of expression status was computed using Cox-Proportional Hazards model implementation (coxph) available in R-library “survival”. Kaplan-Meier survival analysis was used for the analysis of clinical outcome.
  • V W*W*L/2.
  • Tissue microarray (BR20020) was purchased from US Biomax and paraffin-embedded tissue samples were obtained from JWCI and Tan Tock Seng Hospital (TTSH), Singapore. Staining and image analysis of tissue microarray were performed by Histopathology Department from Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore. Anti-EGFR (clone 31G7) was purchased from Invitrogen, Calif., USA and anti-UBASH3B (ab34781) was purchased from Abcam, MA, USA. Image analysis of paraffin-embedded tissue specimens were performed by DH and JW from JWCI.
  • RNA extraction was performed as previously described 6 .
  • Total RNA was assessed for purity by UV spectrophotometry and quantified using the Quant-iT Ribogreen RNA assay kit (Invitrogen, Carlsbad, Calif., USA).
  • RNA was reverse transcribed using the qScript microRNA cDNA synthesis kit (Quanta Biosciences, Gaithersburg, Md., USA). The transcribed cDNA was diluted 10-fold and used as a qPCR template. PerfeCTa® miRNA assay primers were obtained from Quanta Biosciences. Each qPCR reaction contained 4.6 ⁇ L of diluted cDNA, 5 ⁇ L PerfeCTa® SYBR® Green SuperMix (Quanta Biosciences) and miRNA specific forward primer targeting the specific miRNA and universal reverse primer. Each sample was assessed in triplicate in 40 cycles of 95° C. for 5 sec and 60° C. for 30 sec.
  • the CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, Calif.) was used for qPCR with melting-curve analysis.
  • Target amplification for miRNA 200A, B and C was normalized with the reference control (MDA-MB-231) and comparative quantification was recorded at the difference in real-time quantification cycle (Cq) between the target and reference sample ( ⁇ Cq).
  • Cq real-time quantification cycle
  • HCT116 cells were plated at a density of 5 ⁇ 10 4 cells per well in 24-well plate format and transfected with 10 ng of pMIR REPORT containing the respective miRNA responsive regions of UBASH3B 3′ UTR sequence, 40 nM of miRNA mimics and 5 ng of pRL null internal control simultaneously on the next day.
  • the luciferase activities were measured using the Dual Luciferase system (Promega). All luciferase readings were first normalized to corresponding internal control pRL null Renilla luciferase readings. The resulting relative activities were further normalized to appropriate controls.
  • 24-well FluorBlok transwell insert (Falcon) with a pore size of Sum was pre-coated with 500 ug/ml (or 1 mg/ml for prostate cancer cell lines) of growth factor-reduced Matrigel (Falcon) for 3-4 hours at 37° C. 5 ⁇ 10 4 MB231, BT549, DU145, and PC3 with indicated treatments were seeded in each insert with DMEM containing 0.5% FBS. DMEM supplemented with 0.5% FBS and 100 ng/ml EGF was added outside the chamber as a chemoattractant.
  • Invaded cells were fixed after 48 hours of incubation by using 3.7% formaldehyde and stained with 25 ug/ml propidium iodide (Sigma). 10 fields per inserts were scanned and numbers of invaded cells were counted with Cellomics ArrayScan.
  • 96-well plates were pre-coated with 0.6% soft agar.
  • Single cell suspension of target cells were plated at a density of 1500 cells per well containing 100 ul of complete DMEM with 0.5% methylcellulose (Sigma). After 14 days of incubation, cell colonies were stained with 4 ⁇ g/ml p-Iodonitrotetrazolium Violet (INT) overnight and the number of colonies formed was quantified using Optronix Gelcount software.
  • INT p-Iodonitrotetrazolium Violet
  • Single cell suspension of target cells were plated at a density of 1 ⁇ 10 4 cells/well in 6-well ultra-low attachment plates (Corning) containing 3 ml MammoCult medium supplemented with 0.5 ⁇ g/ml hydrocortisone and 4 ⁇ g/ml heparin (STEMCELL Technologies) and cultured for 7 days. Tumorspheres formed were stained with 4 ⁇ g/ml p-Iodonitrotetrazolium Violet (INT) overnight and quantified using Optronix Gelcount software. For EGFR rescue assay, tumospheres formed at day 7 were spun down, trypsinized and re-plated at a density of 1 ⁇ 10 4 cells/well to access the cancer stem cell regeneration capacity.
  • INT p-Iodonitrotetrazolium Violet
  • Cell viability was determined using CellTiter-Glo Luminescent Cell Viability Assay (Promega) as instructed by manufacturer's manual. 1000 cells were plated in 96-well plate and the readings were taken for 5 consecutive days using CellTiter-Glo kit (Promega).
  • MB231-Luc-D3-H2LN MB231-LN
  • MB231-LN MB231-Luc-D3-H2LN
  • MB231, BT549, MCF7, T47D, BT474, MB361, MB415, MB436, Hs578T, MB157, PC3, DU145, HCT116, and HEK293T cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • SKBR3 cells were maintained in McCoy's 5A medium.
  • HCC1806, HCC1937, 22RV1, and LnCap were maintained in RPMI medium supplemented with 10% FBS.
  • MCF10A normal breast epithelial cell line was grown in DMEM/F12 supplemented with 5% horse serum, 20 ng/ml EGF, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 ⁇ g/ml insulin, and penicillin/streptomycin (Invitrogen). All media were supplemented with 5000 U/mL penicillin/streptomycin (Invitrogen). All cells were maintained at 37° C. with 5% CO 2 .
  • EGF EGF
  • HCC1937, 22RV1, and LnCap were maintained in RPMI medium supplemented with 10% FBS.
  • MCF10A normal breast epithelial cell line was grown in DMEM/F12 supplemented with 5% horse serum, 20
  • siRNA and plasmids transfections were conducted using Lipofectamine RNAiMax (Invitrogen) and FugeneHD (Roche Applied Science), respectively
  • target genes from their respective transient expression plasmids were subcloned into the PMN retroviral expression vector.
  • Virally infected cells were sorted based on GFP over-expression.
  • pcDNA4-UBASH3B wild type was cloned using cDNA as the template and pcDNA4-UBASH3B H391A was generated using GeneTailor Site-Directed Mutagenesis kit (Invitrogen).
  • UBASH3B small hairpin RNA constructs were generated by inserting siRNA hairpin oligonucleotides into pSIREN-RetroQ (Clontech Laboratories).
  • Target-specific siRNA and non-targeting control siRNA were purchased from 1st Base Singapore with the following target sequences:
  • UBASH3B siRNA#1 (SEQ ID NO: 1) 5′-CCGGCUUAUUUGAGUGGAC-3′
  • UBASH3B siRNA#2 (SEQ ID NO: 2) 5′-CCUCAUAAGAAGCAGCUAC-3′
  • UBASH3B siRNA#3 (SEQ ID NO: 3) 5′-GCACUGCAACUGAGAAAUU-3′
  • ETS1 siRNA#1 (SEQ ID NO: 4)
  • ETS1 siRNA#2 (SEQ ID NO: 5) 5′-GGAAUUACUCACUGAUAAA-3′
  • CBL siRNA (SEQ ID NO: 6) 5′-CCAAUCACAAGCUUAGUUAUCAGG-3′
  • siRNA were designed by 1st Base Singapore except for ETS1 siRNA#1 which was referenced from a previously published paper 7 .
  • Oligo miRNA mimics and antagomirs were purchased from Dharmacon, Inc. (Chicago, Ill., USA).
  • 30 nM siRNAs, 15 nM miRNA mimics or 100 nM iRNA antagomirs were used to transfect cells. 48 h after transfection cell pellets were collected and subjected indicated assays.
  • TRCN0000099665 targeting 3′UTR: (SEQ ID NO: 41) GCTCAGAATCATTTAGCATAT TRCN0000099669 (targeting CDS): (SEQ ID NO: 42) GCGTTCAGACTGCACATAATA
  • the two control constructs are pLKO1puro empty vector (SHC001) and pLKO1puro Non-Mammalian shRNA Control (SHC002). Virus production, 4T1 cell infection and puromycin selection were carried out according to the manufacturer's instructions.
  • RNA including small RNAs was isolated using RNeasy Mini Kit (Qiagen). The microarray hybridization was performed using the Illumina HumanHT-12 V4.0 expression beadchip, and data analysis was performed using GeneSpring software from Agilent Technologies. Microarray data reported herein have been deposited at the NCBI Gene Expression Omnibus with the accession number GSE36693. Reverse transcription and quantitative PCR assays were performed using High Capacity cDNA Archive kit and KAPA SyBr Fast qPCR kit (KAPA Biosystems), respectively. TaqMan MicroRNA assays were used to quantify the level of mature miRNAs as previously described 8 .
  • Anti-UBASH3B (ab34781) was purchased from Abcam.
  • Anti-EGFR (cs2232), anti-CBL (cs2747) and anti-Pan phosphor-Tyr (cs9411) was purchased from Cell Signaling.
  • Anti-ETS1 (sc350), anti-ZEB1 (sc-2538.8), and anti-ZEB2 (sc-48789) were obtained from Santa Cruz.
  • Anti-Myc and anti-Actin were purchased from Roche Applied Science and Sigma-Aldrich, respectively.
  • Co-IP Co-Immunoprecipitation
  • Co-IP was performed as described previously. 293T and BT549 whole cell lysate were extracted and subjected to immunoprecipitation using ProteinA/G agarose (Roche) according to the manufacturer's instructions. Anti-Myc, anti-Flag M2 affinity gel (#A2220, Sigma), or a non-specific IgG (sc-2025) was used in the co-IP assay.
  • Chromatin Immunoprecipitation (ChIP).
  • ChIP assays were performed as described previously 9 .
  • Pre-cleared chromatin from MDA-MB231 or BT549 cells was immunoprecipitated with anti-ETS1 (sc350).
  • the immunoprecipitated DNA was quantitated by real-time quantitative PCR using KAPA SyBr Fast qPCR kit (KAPA Biosystems). The enrichment of specific genomic regions was assessed relative to the input DNA followed by normalization to the respective control IgG values. Primer sequences were listed in Table 2.
  • the latest and most annotated Illumina HumanHT-12 V4.0 expression Beadchip was used to profile the gene expression of a panel of basal-like (often related to TNBC) and luminal type (non-TNBC) of human breast cancer cell lines and primary tumor tissues.
  • a set of 103 genes were identified to be overexpressed in both TNBC cell lines and tissues compared to respective non-TNBC counterparts ( FIG. 1( h ) and Table 3 below).
  • 19 were annotated as enzymes and hence considered potential “druggable” targets.
  • seven of these genes show significant association with disease outcome in at least one examined breast cancer cohorts ( FIG. 1( i ) ).
  • MB231 MDA-MB-231
  • siRNAs small interference RNA oligos
  • the efficiencies of the gene knockdown were monitored by quantitative RT-PCR and the phenotypic changes were assessed on the 3-dimensional (3D) Matrigel growth as an indicator of malignant growth.
  • the results showed that 5 out of 7 these genes (UBASH3B, AGPAT4, ACOT9, CDK6, and HYAL3) may be required for TNBC progression as their knockdown strongly reduced the Matrigel growth of MB231 cells ( FIG. 1( b ) ).
  • UBASH3B also called Suppressor of T-cell receptor signaling 1 (STS-1)
  • STS-1 T-cell receptor signaling 1
  • STS-1 Suppressor of T-cell receptor signaling 1
  • UBASH3B is a Transcriptional Target of ETS1
  • ETS1 is known to be an invasive factor associated with aggressive tumors 12 . Echoing the UBASH3B expression, ETS1 was also overexpressed in invasive breast cancer cell lines and clinical tumor samples but not in non-invasive counterparts ( FIG. 2( b ) and FIGS. 2( h ) and 2( i ) ).
  • Chromatin immunoprecipitation (ChIP) analysis showed a remarkable enrichment of ETS1 in the UBASH3B core promoter in TNBC MB231 and BT549 cells ( FIG. 2( c ) ), supporting a direct regulation of UBASH3B by ETS1.
  • ETS1 knockdown resulted in downregulation of UBASH3B expression in invasive breast cancer BT549 as well as prostate cancer DU145 and PC3 cells ( FIG. 2( d ) and FIG. 2( j ) ).
  • MAPK inhibitor U0126 treatment in MB231 cells was seen to decrease the UBASH3B expression in a time-dependent manner ( FIG. 2( e ) ).
  • ETS1 and UBASH3B expression seemed to be correlated well in clinical breast tumor samples in general ( FIG. 2( f ) , left), and also co-upregulated in organ-specific metastases ( FIG. 2( f ) , right). Similar to UBASH3B, ETS1 expression is also associated with lung and brain but not bone metastasis in the same GSE12276 cohort ( FIG. 2( g ) ), verifying a clinical relevance of ETS1-UBASH3B regulation.
  • UBASH3B is Also a Target of miR-200a
  • UBASH3B 3′ UTR contains sites for miR-200a, but not for miR-200b/c
  • a direct and specific targeting and inhibition of UBASH3B by miR-200a, but not by miR-200c was demonstrated using UBASH3B 3′-UTR reporters that contains the wild type or a variant in which the miR-200a binding sequences were mutated ( FIG. 3( c ) ).
  • UBASH3B 3′-UTR reporters that contains the wild type or a variant in which the miR-200a binding sequences were mutated
  • UBASH3B overexpression in tumorigenesis was next assessed. As UBASH3B is implicated in antagonizing EGFR degradation during endocytosis upon EGF treatment 10 , whether UBASH3B has a role in EGF-induced invasion, a process of particular relevance in TNBC, was investigated. UBASH3B knockdown by two independent siRNAs accentuated EGFR protein degradation and resulted in marked inhibition of EGF-induced transwell invasion in invasive breast and prostate cancer cells ( FIG. 4( a ) and FIG. 4( h ) ). This observation is consistent with known role of EGFR as a well-established invasive effector in TNBC and other invasive tumors 18-20 .
  • UBASH3B knockdown In addition to affecting cell invasion, UBASH3B knockdown also reduced the ability of breast and prostate cancer cells to form tumorspheres ( FIGS. 4( k ) and 4( l ) ), a growth feature associated with cancer stem cells, while, notably, UBASH3B knockdown did not affect cell proliferation when grown on monolayer ( FIG. 4 ( m ) ). This indicates that UBASH3B is not required for cell proliferation in general but more involved in regulating cellular phenotypes associated with malignancy.
  • UBASH3B depleted tumors appeared to be irresponsive to Erlotinib treatment while the control tumors showed marked growth inhibition following the treatment ( FIG. 4( f ) ).
  • ectopic overexpression of EGFR in UBASH3B-depleted MB231 restored the sensitivity of the cells to Erlotinib treatment ( FIG. 4( g ) ), further validating that the resistance towards Erlotinib caused by UBASH3B knockdown was due to EGFR reduction.
  • TNBC tends to have early recurrence presented with distant metastasis after adjuvant chemotherapy.
  • anti-EGFR treatment in TNBC could enhance the response to chemotherapy 22 .
  • UBASH3B depletion could also sensitize TNBC cells towards Paclitaxel, a chemotherapeutic agent mainly used for metastatic TNBC.
  • the result shows that depletion of UBASH3B significantly increased the sensitivity of MB231 towards Paclitaxel, by reducing EC50 from 4.53 nM to 0.61 nM ( FIG. 5( l ) ).
  • LM231 subline L1
  • shNB1 shUBASH3B#1
  • shUBASH3B#2 KD2
  • FIG. 5( a ) Tail vein injection of these cells resulted in lung metastasis in nude mice.
  • BLI measurement revealed significant lung metastasis reduction by KD cells comparing to control, with 50% and 77% reduction of metastasis burden at week 4 after injection by KD1 and KD2, respectively ( FIG. 5( b )-( d ) ), which corresponded well to the respective knockdown efficiency in these cells.
  • UBASH3B knockdown strongly inhibited the lung metastasis ( FIG. 5( f )-( j ) ).
  • UBASH3B As UBASH3B has been recently shown to be a tyrosine phosphatase 11 , the inventors explored whether the phosphatase activity is required for its invasion-promoting capacity. To achieve this, a phosphatase-dead mutant UBASH3B (H391A) 11 was made and compared with the wild type UBASH3B for their abilities to promote cell invasion. While the overexpression of wild type UBASH3B in BT549 and MB231 cells promoted both basal and EGF-induced invasion robustly, UBASH3B (H391A) failed to do so ( FIG. 6( a ) ).
  • the inventors further showed that UBASH3B knockdown-induced EGFR degradation could be restored by the concomitant CBL knockdown ( FIG. 6( f ) ), indicating an antagonistic role of CBL in promoting UBASH3B-induced EGFR stabilization.
  • the data support the hypothesis that UBASH3B promotes invasion and aggressive growth by promoting EGFR stability through dephosphorylation and inhibition of CBL function.
  • the oncogenic phosphatase activity of UBASH3B allows it to emerge as an excellent new therapeutic target for cancer invasion and metastasis.
  • UBASH3B overexpression in TNBC and its fundamental role as a tyrosine phosphatase in invasive progression and disease outcome, the inventors contend that UBASH3B overexpression is an important oncogenic event in TNBC. Importantly, UBASH3B acts to bridge several key invasive pathways, raising a possibility that therapeutic targeting UBASH3B may provide additional benefits for TNBC patients.
  • UBASH3B upregulation in TNBC can be the result of deregulation of ETS1 and miR-200a, two key molecules whose functions are often associated with cancer invasion.
  • the inventors showed UBASH3B is a direct target of both ETS1 and miR-200a and thus upregulation of UBASH3B could be a combined result of ETS1 overexpression and miR-200a downregulation in TNBC.
  • UBASH3B does not seem to affect EMT as its knockdown neither change cell morphology nor the expression of EMT markers such as E-cadherin and Vimentin (data not shown) Therefore, UBASH3B may coordinate with other miR-200 targets to promote invasive capacity to enable extravasation and subsequent migration to distal sites. It has been shown that when circulating cancer cells colonize a distal site for instance lung, miR-200 needs to be re-expressed to induce mesenchymal-to-epithelial transition (MET), a rate-limiting step to allow attachment and colonization of the new, niche 24 . Thus, UBASH3B expression may not be required during that late stages of metastasis progression, its role in after metastasis colonization may need further investigations.
  • MET mesenchymal-to-epithelial transition
  • TNBC harbors an overall induction of protein tyrosine phosphorylation activity due to activation of a number of receptor tyrosine kinases such as EGFR and MET as well as non receptor tyrosine kinases Src 25 .
  • receptor tyrosine kinases such as EGFR and MET
  • non receptor tyrosine kinases Src 25 .
  • other protein phosphatases such as PTEN and PTPN12 often function as tumor suppressors that are inactivated in TNBC 26-27 .
  • UBASH3B as a tyrosine phosphatase may most likely exert its oncogenic function by selectively targeting a specific tumor suppressive tyrosine phosphorylation event.
  • tyrosine phosphatase PTP1B that has been shown to be oncogenic through inhibiting the growth inhibitory Src Y530 phosphophorylaton in prostate and colon cancers 28 .
  • SHP2 another tyrosine phosphatases SHP2 in breast cancer progression 29 , though its association with TNBC as well as the direct targets for dephosphorylation are yet to be elucidated.
  • CBL is long known to have dual roles in oncogenesis, one of which is the tumor suppressive function whereby CBL acts as an ubiquitin ligase to degrade multiple oncogenic tyrosine kinases including EGFR 30 , while its oncogenic role has been linked to its ability to be recruited to activated receptors and served as adaptor for the docking of downstream kinases cascade to relay the oncogenic signaling 31 .
  • the tumor suppressive ubiqutin ligase activity is associated with the phosphorylation at tyrosine residue 371, though other phosphorylation sites have been linked to its oncogenic activity 32 .
  • the inventors showed that UBASH3B is able to bind to and dephosphorylate CBL using a pan-tyrosine phosphorylation antiobody, leading to EGFR stabilization. It will be interesting to investigate in the future whether UBASH3B specifically targets Y371 or other phosphorylation sites. Although it is possible that UBASH3B may have effects on both tumor suppressive and oncogenic phosphorylation sites, it may preferentially modulate CBL towards the oncogenic activity when it is overexpressed in aggressive cancers like TNBC.
  • EGFR protein level was reduced due to the increase ubiquitin ligase activity of CBL.
  • EGFR is known to be overexpressed in TNBC, though EGFR-based therapy alone in TNBC has failed to show an expected response.
  • the inventors have shown that depletion of UBASH3B has phenocopied EGFR inhibitor Erlotinib treatment in vivo ( FIG. 4( f ) ).
  • xenograft tumors depleted of UBASH3B were no longer sensitive to Erlotinib treatment.
  • UBASH3B level might be an important determinant of EGFR inhibitor response in TNBC.
  • TNBC patients with both high EGFR and UBASH3B levels might be more responsive to therapeutic targeting of EGFR.
  • targeting EGFR in combination with chemotherapy has shown benefits to TNBC patients in a recent clinical trial 22 .
  • TNBC cells were treated with a chemotherapy drug, Paclitaxel, it showed sensitization in the cell line with UBASH3B depleted. This supports the notion that targeting UBASH3B could be an alternative approach to EGFR inhibition, especially in the cases when the cells develop resistance to EGFR inhibitors.
  • UBASH3B The preferential regulation of UBASH3B on aggressive tumor behaviors such as invasion, metastasis and tumorsphere formation, but not cell proliferation, suggests that therapeutic targeting of UBASHB may provide cancer selectivity and safety, making it an attractive approach for cancer therapy.
  • the disclosed modulator compounds and compositions thereof may be used in the disclosed methods to treat cancer, particularly to reduce cancer invasiveness and metastasis, by modulating expression of the UBASH3B gene, and/or the activity of the UBASH3B protein or a functional variant thereof.
  • the disclosed modulator compounds and compositions thereof may also be used to sensitize or re-sensitize a cancer patient to a treatment with one or more chemotherapeutic agents, by modulating expression of the UBASH3B gene, and/or the activity of the UBASH3B protein or a functional variant thereof.
  • Also disclosed are methods that may be used to predict disease outcome, aid selection of a suitable treatment for a cancer patient, and optimize the treatment regimen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US14/348,365 2011-09-28 2012-09-28 Methods and pharmaceutical compositions for treating cancer Expired - Fee Related US9334500B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SG2011070364 2011-09-28
SG201107036 2011-09-28
SG201107036-4 2011-09-28
PCT/SG2012/000364 WO2013048345A1 (en) 2011-09-28 2012-09-28 Methods and pharmaceutical compositions for treating cancer

Publications (2)

Publication Number Publication Date
US20140335106A1 US20140335106A1 (en) 2014-11-13
US9334500B2 true US9334500B2 (en) 2016-05-10

Family

ID=47996102

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/348,365 Expired - Fee Related US9334500B2 (en) 2011-09-28 2012-09-28 Methods and pharmaceutical compositions for treating cancer

Country Status (4)

Country Link
US (1) US9334500B2 (de)
EP (1) EP2760457A4 (de)
SG (1) SG11201400976WA (de)
WO (1) WO2013048345A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN106822100A (zh) * 2017-01-19 2017-06-13 广东工业大学 一种组合物和药物制剂及其应用
CN106868146B (zh) * 2017-03-06 2020-01-24 新乡医学院 用于检测与结直肠癌长春新碱耐药相关的miRNA表达的引物、试剂盒、方法及应用
CN110938630B (zh) * 2019-12-20 2023-07-28 中国人民解放军第四军医大学 人b3gnt5基因的用途及相关产品
EP4277991A1 (de) * 2021-01-12 2023-11-22 Georgia Tech Research Corporation Kombinationstherapeutika zur behandlung proliferativer erkrankungen

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002589A1 (en) 1998-07-09 2000-01-20 Monash University Modulation of haemopoietic cell activity and agents useful for same
WO2005027830A2 (en) 2003-09-12 2005-03-31 Virginia Commonwealth University Chimeric transcription factor decoy oligonucleotides
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US20060194883A1 (en) 2003-04-23 2006-08-31 Eisai Co., Ltd Mmp expression inhibitor
WO2008043561A2 (en) 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
WO2010017443A2 (en) 2008-08-07 2010-02-11 Da Zen Group, Llc Anti-beta-2-microglobulin agents and the use thereof
WO2010103416A2 (en) * 2009-03-10 2010-09-16 Lam Research Corporation Method of particle contaminant removal
US7820809B2 (en) 2002-11-14 2010-10-26 Dharmacon, Inc. Functional and hyperfunctional siRNA directed against Bcl-2
WO2011005793A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Cell-based bioprocessing
US20110021607A1 (en) * 2008-02-01 2011-01-27 Michael Clarke Methods and Compositions Relating to Carcinoma Stem Cells
US20120070450A1 (en) * 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
WO2012071492A1 (en) 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells
US20130137584A1 (en) * 2010-02-01 2013-05-30 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2008034133A2 (en) * 2006-09-15 2008-03-20 Temple University - Of The Commonwealth System Of Higher Education Effect of tula on hiv

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
WO2000002589A1 (en) 1998-07-09 2000-01-20 Monash University Modulation of haemopoietic cell activity and agents useful for same
US7820809B2 (en) 2002-11-14 2010-10-26 Dharmacon, Inc. Functional and hyperfunctional siRNA directed against Bcl-2
US20060194883A1 (en) 2003-04-23 2006-08-31 Eisai Co., Ltd Mmp expression inhibitor
WO2005027830A2 (en) 2003-09-12 2005-03-31 Virginia Commonwealth University Chimeric transcription factor decoy oligonucleotides
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
WO2008043561A2 (en) 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
US20110021607A1 (en) * 2008-02-01 2011-01-27 Michael Clarke Methods and Compositions Relating to Carcinoma Stem Cells
WO2010017443A2 (en) 2008-08-07 2010-02-11 Da Zen Group, Llc Anti-beta-2-microglobulin agents and the use thereof
WO2010103416A2 (en) * 2009-03-10 2010-09-16 Lam Research Corporation Method of particle contaminant removal
US20120070450A1 (en) * 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
WO2011005793A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Cell-based bioprocessing
US20130137584A1 (en) * 2010-02-01 2013-05-30 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2012071492A1 (en) 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"International Application No. PCT/SG2012/000364, International Search Report and Written Opinion mailed Dec. 7, 2012", 32 pgs.
Benedict et al. (J. Exp. Medicine, 2001, 193(1) 89-99). *
Carter, S. K. et al. (Chemotherapy of Cancer; Second edition; John Wiley & Sons: New York, 1981; appendix C). *
Gerdes et al. (Front. Oncol. Dec. 18, 2014 doi: 10.3389/fonc.2014.00366, pp. 1-12). *
Gura (Science, 1995, 270:575-577). *
Gura (Science, 1997, 278:1041-1042). *
Ito, Hiromichi, et al., "Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2", Cancer Research, 64(20), (2004), 7439-7446.
Jiang et al. (J. Biol. Chem., 2003, 278(7) 4763-4769). *
Kaiser (Science, 2006, 313: 1370). *
Kita, Daisuke, et al., "Expression of Dominant-negative Form of Ets-1 Suppresses Fibronectin-stimulated Cell Adhesion and Migration Through Down-Regulation of Integrin alpha5 Expression in U251 Glioma Cell Line", Cancer Research, 61, (2001), 7985-7991.
Kita, Daisuke, et al., "Expression of Dominant-negative Form of Ets-1 Suppresses Fibronectin-stimulated Cell Adhesion and Migration Through Down-Regulation of Integrin α5 Expression in U251 Glioma Cell Line", Cancer Research, 61, (2001), 7985-7991.
Krontiris and Capizzi (Internal Medicine, 4th Edition, Editor-in-chief Jay Stein, Elsevier Science, 1994 Chapters 71-72, pp. 699-729). *
Matsushita et al. (FEBS Letters, 1999, vol. 443, pp. 348-352). *
Pei and Tuschl (Nature Methods, 2006, 3: 670-676). *
Sekar et al. (Theranostics 2013 3(12): 964-985). *
Singh et al. (Glycobiology, 2001, vol. 11, pp. 587-592). *
Sureban, Sripathi, et al., "Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism", Journal of Nanobiotechnology, 9(40), (2011), 1-13.
Xia, Hongping, et al., "miR-200a Regulates Epithelial-Mesenchymal to Stem-like Transition via ZEB2 and beta-Catenin Signaling", The Journal of Biological Chemistry, 5(47), (2010), 36995-37004.
Xia, Hongping, et al., "miR-200a Regulates Epithelial-Mesenchymal to Stem-like Transition via ZEB2 and β-Catenin Signaling", The Journal of Biological Chemistry, 5(47), (2010), 36995-37004.
Zhang, Yan, et al., "miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer", Cancer Research, 71(10), (2011), 3552-3562.
Zhao, Jian, et al., "Thirty-Kilodalton Tat-Interacting Protein Suppresses Tumor Metastasis by Inhibition of Osteopontin ranscription in Human Hepatocellular Carcinoma", Hepatology, 48(1), (2003), 265-275.

Also Published As

Publication number Publication date
WO2013048345A1 (en) 2013-04-04
EP2760457A4 (de) 2015-07-08
SG11201400976WA (en) 2014-04-28
US20140335106A1 (en) 2014-11-13
EP2760457A1 (de) 2014-08-06

Similar Documents

Publication Publication Date Title
Sethuraman et al. SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway
US10406128B2 (en) Treatment and diagnosis of colon cancer
JP2022050493A (ja) 癌を治療する方法における使用のための毛細血管拡張性運動失調症の変異したＲａｄ３関連タンパク質キナーゼ（ＡＴＲ）の阻害剤
US9334500B2 (en) Methods and pharmaceutical compositions for treating cancer
US20230383365A1 (en) Cancer treatments and methods of selecting same
Tanaka et al. Targeting Aurora kinase A suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo
US20160038498A1 (en) Methods for the treatment of cancer
Zhang et al. Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC)
Du et al. Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer
Yi et al. Circular RNA circ_0004507 contributes to laryngeal cancer progression and cisplatin resistance by sponging miR‐873 to upregulate multidrug resistance 1 and multidrug resistance protein 1
Fujiwara et al. A Nucleolar Stress–Specific p53–miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network
Wang et al. PIK3CA is regulated by CUX1, promotes cell growth and metastasis in bladder cancer via activating epithelial-mesenchymal transition
EP3092492B1 (de) Behandlung von mutiertem p53 exprimierenden tumoren
US9187787B2 (en) Method of diagnosing and treating cancer
US20140275201A1 (en) Identification of cancer stem cell markers and use of inhibitors thereof to treat cancer
Jiang et al. MicroRNA-149 inhibits the progression of lung adenocarcinoma through targeting RAP1B and inactivating Wnt/β-catenin pathway.
WO2018056301A1 (ja) 癌幹細胞阻害剤及びその使用
Zhang et al. WIF1 promoter hypermethylation induce endometrial carcinogenesis through the Wnt/β‐catenin signaling pathway
US11459567B2 (en) Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer
US20220186227A1 (en) Therapeutic Targets for Oncogenic KRAS-Dependent Cancers
Sexton XPO1 as a Therapeutic Target in Gastric Cancer
McMellen Signaling Mechanisms Driving Parp Inhibitor Resistance in High Grade Serous Ovarian Cancer
US20200325539A1 (en) Cancer biomarkers and methods of use
Ma et al. MBIP promotes ESCC metastasis by activating MAPK pathway
Mody Investigation of Micro-RNA-based Approaches to Overcome Epithelial-Mesenchymal Transition in Pancreatic Cancer

Legal Events

Date Code Title Description
AS Assignment

Owner name: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, SINGA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YU, QIANG;LEE, SHUET THENG;REEL/FRAME:033025/0555

Effective date: 20121218

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20200510